US20180318165A1 - Tissue treatment device and method - Google Patents
Tissue treatment device and method Download PDFInfo
- Publication number
- US20180318165A1 US20180318165A1 US15/771,841 US201615771841A US2018318165A1 US 20180318165 A1 US20180318165 A1 US 20180318165A1 US 201615771841 A US201615771841 A US 201615771841A US 2018318165 A1 US2018318165 A1 US 2018318165A1
- Authority
- US
- United States
- Prior art keywords
- reactor
- pressure device
- controlled pressure
- air
- enclosed volume
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000011282 treatment Methods 0.000 title claims description 5
- 238000000034 method Methods 0.000 title description 22
- 239000007788 liquid Substances 0.000 claims abstract description 62
- 239000002537 cosmetic Substances 0.000 claims abstract description 55
- 239000006071 cream Substances 0.000 claims abstract description 38
- 239000007789 gas Substances 0.000 claims description 68
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 38
- 239000001301 oxygen Substances 0.000 claims description 38
- 229910052760 oxygen Inorganic materials 0.000 claims description 38
- 239000012528 membrane Substances 0.000 claims description 34
- 239000000758 substrate Substances 0.000 claims description 14
- 230000004888 barrier function Effects 0.000 claims description 11
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 9
- 229910052725 zinc Inorganic materials 0.000 claims description 9
- 239000011701 zinc Substances 0.000 claims description 9
- 230000002093 peripheral effect Effects 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 6
- 229910052744 lithium Inorganic materials 0.000 claims description 5
- 230000002000 scavenging effect Effects 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- AJLNZWYOJAWBCR-OOPVGHQCSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O AJLNZWYOJAWBCR-OOPVGHQCSA-N 0.000 claims description 4
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 4
- 239000003638 chemical reducing agent Substances 0.000 claims description 4
- 229960002887 deanol Drugs 0.000 claims description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 4
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 239000004909 Moisturizer Substances 0.000 claims description 2
- 229940095094 acetyl hexapeptide-8 Drugs 0.000 claims description 2
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 claims description 2
- 229940061720 alpha hydroxy acid Drugs 0.000 claims description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims description 2
- YSZKOFNTXPLTCU-UHFFFAOYSA-N barium lithium Chemical compound [Li].[Ba] YSZKOFNTXPLTCU-UHFFFAOYSA-N 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 2
- 238000004891 communication Methods 0.000 claims description 2
- 239000008151 electrolyte solution Substances 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 2
- PNXOJQQRXBVKEX-UHFFFAOYSA-N iron vanadium Chemical compound [V].[Fe] PNXOJQQRXBVKEX-UHFFFAOYSA-N 0.000 claims description 2
- 235000019136 lipoic acid Nutrition 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 230000001333 moisturizer Effects 0.000 claims description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 2
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960003471 retinol Drugs 0.000 claims description 2
- 235000020944 retinol Nutrition 0.000 claims description 2
- 239000011607 retinol Substances 0.000 claims description 2
- 229960004889 salicylic acid Drugs 0.000 claims description 2
- 229960002663 thioctic acid Drugs 0.000 claims description 2
- PMTRSEDNJGMXLN-UHFFFAOYSA-N titanium zirconium Chemical compound [Ti].[Zr] PMTRSEDNJGMXLN-UHFFFAOYSA-N 0.000 claims description 2
- 229940035936 ubiquinone Drugs 0.000 claims description 2
- 239000003570 air Substances 0.000 description 80
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 13
- 239000000463 material Substances 0.000 description 11
- 230000000699 topical effect Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000000853 adhesive Substances 0.000 description 5
- 230000001070 adhesive effect Effects 0.000 description 5
- 239000012080 ambient air Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 3
- 230000001351 cycling effect Effects 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- -1 for example Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000003487 electrochemical reaction Methods 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- 229920003043 Cellulose fiber Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002070 nanowire Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/05—Bandages or dressings; Absorbent pads specially adapted for use with sub-pressure or over-pressure therapy, wound drainage or wound irrigation, e.g. for use with negative-pressure wound therapy [NPWT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H9/00—Pneumatic or hydraulic massage
- A61H9/005—Pneumatic massage
- A61H9/0057—Suction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H9/00—Pneumatic or hydraulic massage
- A61H9/005—Pneumatic massage
- A61H9/0071—Pneumatic massage by localized pressure, e.g. air streams or jets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/60—Containers for suction drainage, adapted to be used with an external suction source
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/64—Containers with integrated suction means
- A61M1/65—Containers with integrated suction means the suction means being electrically actuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/80—Suction pumps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
- A61M1/92—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing with liquid supply means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
- A61M1/94—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing with gas supply means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
- A61M1/96—Suction control thereof
- A61M1/962—Suction control thereof having pumping means on the suction site, e.g. miniature pump on dressing or dressing capable of exerting suction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
- A61M1/98—Containers specifically adapted for negative pressure wound therapy
- A61M1/984—Containers specifically adapted for negative pressure wound therapy portable on the body
- A61M1/985—Containers specifically adapted for negative pressure wound therapy portable on the body the dressing itself forming the collection container
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M35/00—Devices for applying media, e.g. remedies, on the human body
- A61M35/30—Gas therapy for therapeutic treatment of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0468—Specially adapted for promoting wound healing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0472—Structure-related aspects
- A61N1/0492—Patch electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00727—Plasters means for wound humidity control
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/02—Characteristics of apparatus not provided for in the preceding codes heated or cooled
- A61H2201/0221—Mechanism for heating or cooling
- A61H2201/0278—Mechanism for heating or cooling by chemical reaction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/10—Characteristics of apparatus not provided for in the preceding codes with further special therapeutic means, e.g. electrotherapy, magneto therapy or radiation therapy, chromo therapy, infrared or ultraviolet therapy
- A61H2201/105—Characteristics of apparatus not provided for in the preceding codes with further special therapeutic means, e.g. electrotherapy, magneto therapy or radiation therapy, chromo therapy, infrared or ultraviolet therapy with means for delivering media, e.g. drugs or cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/12—Driving means
- A61H2201/1238—Driving means with hydraulic or pneumatic drive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/16—Physical interface with patient
- A61H2201/1602—Physical interface with patient kind of interface, e.g. head rest, knee support or lumbar support
- A61H2201/165—Wearable interfaces
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
- A61M1/96—Suction control thereof
- A61M1/964—Suction control thereof having venting means on or near the dressing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/02—General characteristics of the apparatus characterised by a particular materials
- A61M2205/0272—Electro-active or magneto-active materials
- A61M2205/0277—Chemo-active materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/05—General characteristics of the apparatus combined with other kinds of therapy
- A61M2205/051—General characteristics of the apparatus combined with other kinds of therapy with radiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/05—General characteristics of the apparatus combined with other kinds of therapy
- A61M2205/054—General characteristics of the apparatus combined with other kinds of therapy with electrotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/36—General characteristics of the apparatus related to heating or cooling
- A61M2205/364—General characteristics of the apparatus related to heating or cooling by chemical reaction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/065—Light sources therefor
- A61N2005/0651—Diodes
- A61N2005/0652—Arrays of diodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0616—Skin treatment other than tanning
Definitions
- Negative pressure has been used to generate a partial vacuum to aid in removing impurities from the pores.
- Negative pressure is a term used to describe a pressure that is below normal atmospheric pressure. At room temperature and at sea level, a defined volume of air contains molecules moving in random directions, and these moving molecules exert a force that is equal to the normal atmospheric pressure of approximately 760 mmHg (about 1 bar). Negative pressure has been achieved by removing air from an area of interest, for example at a tissue site via a suction pump.
- the cupping technique which relates to positioning a mouth of a rigid vessel containing hot air on a human's skin
- Spring powered syringes and suction cups are other mechanical techniques that have been used for generating a partial vacuum on human tissue.
- such other mechanical techniques have offered a limited topical negative pressure duration and little or no range of neutral to positive pressures. This is due to design constraints and that the cupping technique and other mechanical techniques are not self-contained and can hinder a user's mobility.
- powered systems which include a vacuum generation source such as a pump
- many examples of such systems are used today for skin treatments and restorative purposes like the temporary removal of wrinkles.
- Many of these systems are not convenient for users.
- Such known systems can be large, heavy, noisy, uncomfortable, and not simple for users to apply and initiate a controlled pressure condition.
- Such known systems also rely on an outside power or vacuum source to create topical negative pressure conditions.
- a controlled pressure device includes a reactor housing element and a reactor.
- the reactor housing element is configured to at least partially define an at least substantially air-tight enclosed volume around a tissue site when fixed in space in relation to the tissue site.
- the reactor is positioned in the enclosed volume and is configured to react with a selected gas found in air. The reactor consumes the selected gas within the enclosed volume.
- a controlled pressure device can include a reactor housing element and a reactor.
- the reactor housing element is configured to at least partially define an at least substantially air-tight enclosed volume around a tissue site when fixed in space in relation to the tissue site, and the enclosed volume has a determined volume (DV).
- the reactor is positioned in the enclosed volume and is configured to react with a selected gas found in air. The reactor consumes the selected gas within the enclosed volume.
- the reactor is configured having a predetermined scavenging capacity (SC) for the selected gas.
- SC scavenging capacity
- the controlled pressure device is configured to have a maximum leakage rate (LR) when affixed to a subject's skin for air entering the enclosed volume.
- the controlled pressure device is also configured to a minimum wear time (MWT) and is configured according to the following relationship: SC>DV*(% of selected gas in air)+LR*(% of selected gas in air)*MWT.
- method of treating a tissue site includes removing a release layer from a reactor housing element.
- the method further includes placing the reactor housing element, a reactor and a liquid impermeable—air permeable membrane over the tissue site.
- the method also includes affixing the reactor housing element with respect to skin around the tissue site to define an at least substantially air-tight enclosed volume around the tissue site.
- FIG. 1 is a schematic cross-sectional view of a controlled pressure device.
- FIG. 2 is a schematic exploded perspective view of a controlled pressure device.
- FIGS. 3 and 4 are schematic depictions of alternative reactor embodiments that can be used with the controlled pressure device shown in FIG. 1 .
- FIGS. 5-7 are schematic depictions of powered components that can be used with the controlled pressure device shown in FIG. 1 .
- FIGS. 8 and 9 are flow diagrams depicting a method of treating a tissue site.
- FIG. 1 depicts a controlled pressure device 10 including a reactor housing element 14 and a reactor 16 .
- the controlled pressure device 10 can be used in conjunction with a cosmetic liquid or cream for tissue treatment.
- the controlled pressure device 10 can include or be used in conjunction with a pad, which can be wetted or impregnated with a cosmetic liquid or cream, and will be hereinafter referred to as a cosmetic pad 18 .
- the controlled pressure device 10 can be positioned at a tissue site 20 to enhance tissue treatment including, but not limited to, wound healing, reduction of skin wrinkles, and other skin maladies.
- the reactor housing element 14 is configured to at least partially define an at least substantially air-tight enclosed volume 22 around the tissue site 20 when affixed in space in relation to the tissue site 20 .
- the reactor housing element 14 in contact with the tissue (e.g., skin) around the tissue site 20 , however, the reactor housing element 14 can be fixed in space in relation to the tissue site 20 without being in direct contact with the tissue around the tissue site 20 .
- an intermediate membrane or layer such as a skin contacting element 24 ( FIG. 2 ) could be interposed between the reactor housing element 14 and the tissue (e.g., skin) around the tissue site 20 , although the reactor housing element 14 is fixed in space in relation to the tissue site 20 .
- the reactor 16 positioned in the enclosed volume 22 reacts with a selected gas found in air and consumes the selected gas within the enclosed volume 22 .
- the cosmetic liquid or cream is also located in the enclosed volume 22 .
- the controlled pressure device 10 can includes the skin contacting element 24 .
- the skin contacting element 24 includes a skin contacting side 30 that is adherable to a subject's skin and an interface side 32 , which is opposite to the skin contacting side.
- the skin contacting element 24 is shown as a separate element from the reactor housing element 14 .
- the skin contacting element 24 can be provided as part of the reactor housing element 14 , e.g., the skin contacting element 24 can be integrally formed with the reactor housing element 14 or connected with the reactor housing element 14 at the manufacturing facility.
- the skin contacting element 24 can be made from a thin sheet-like membrane, for example using a roll-to-roll process.
- the skin contacting element 24 also includes openings 34 extending through the skin contacting element 24 from the skin contacting side 30 to the interface side 32 .
- the openings 34 can be located over the tissue site 20 .
- the skin contacting element 24 is configured to provide a seal around the tissue site 20 to allow for topical negative pressure to be applied at the tissue site 20 .
- the skin contacting element 24 can include an opening that is larger than each of the openings 34 depicted in FIG. 2 .
- the opening 34 can be dimensioned to fit around the tissue site 20 .
- the opening 34 in this example can be similarly shaped to the cosmetic pad 18 so that the skin contacting element 24 and the skin contacting gasket 36 provide a seal around the tissue site 20 ( FIG. 1 ) and the cosmetic pad 18 .
- the skin contacting element 24 need not include the opening(s) 34 , and in this example, the cosmetic pad 18 can be positioned beneath the skin contacting side 30 so as to come in contact with the subject's skin at the tissue site 20 .
- Both the skin contacting side 30 and the interface side 32 are generally flat or planar.
- the interface side 32 is the upper side of the skin contacting element 24 and the skin contacting side 30 is the lower side of the skin contacting element.
- Adhesive 38 (depicted schematically in FIG. 2 ) can provided on the skin contacting side 30 to allow the skin contacting side 30 to adhere to the subject's skin around the tissue site 20 .
- the skin contacting gasket 36 can be provided on the skin contacting side 30 of the skin contacting element 24 or simply be positioned between the skin contacting side 30 and the subject's skin.
- the skin contacting gasket 36 can be made from a hydrogel to further promote sealing around the tissue site 20 to promote the topical negative pressure at the tissue site 20 .
- a release layer 40 can be provided with the controlled pressure device 10 to protect the skin contacting side 30 of the skin contacting element 24 .
- the release layer 40 can be similar to known release layers and include an upper side 42 that is releasable from the skin contacting side 30 of the skin contacting element 24 .
- the release layer 40 also includes a lower surface 44 opposite the upper side 42 .
- the reactor 16 reacts with a selected gas found in air and consumes the selected gas within the enclosed volume 22 .
- the release layer 40 can provide an air-tight barrier such that air is precluded from access to the reactor 16 until after the release layer 40 is removed from the skin contacting element 24 .
- the release layer 40 can cooperate with the reactor housing element 14 in a similar manner, and the release layer 40 can provide an air-tight barrier such that air is precluded from access to the reactor 16 until after the release layer 40 is removed from the reactor housing element 14 .
- the reactor housing element 14 at least partially defines the enclosed volume 22 around the tissue site 20 when fixed in space in relation to the tissue site 20 .
- the reactor housing element 14 cooperates with the skin contacting element 24 to at least partially define the enclosed volume 22 (see FIG. 1 ) around the tissue site 20 , for example, when the skin contacting side 30 of the skin contacting element 24 is in contact with and adhered to the subject's skin and the reactor housing element 14 is affixed to the skin contacting element 24 .
- the reactor housing element 14 can be formed with a hood 50 and a lower peripheral section 52 that at least partially surrounds the hood 50 .
- the lower peripheral section 52 entirely surrounds the hood 50 , which is raised in relation to the lower peripheral section 52 so as to define the enclosed volume 22 around the tissue site 20 .
- the reactor housing element 14 can also be formed without the hood 50 , i.e., the reactor housing element 14 could initially be planar. Similar to the skin contacting element 24 , the reactor housing element 14 can be made from a thin sheet-like membrane, for example using a roll-to-roll process. The reactor housing element 14 can be made from a flexible material that is similar to or the same flexibility as the skin contacting element 24 , which allows the controlled pressure device 10 to conform to the skin around the tissue site 20 .
- the reactor 16 is located between the reactor housing element 14 and the cosmetic pad 18 and the skin contacting element 24 . Since the reactor housing element 14 is made from a flexible material in this example, the section of the reactor housing element 14 that is not in contact with the skin contacting element 24 is raised or offset from the tissue site 20 so as to form the hood 50 .
- the reactor housing element 14 can be made from a material that is air impermeable so that air is precluded or greatly inhibited from entering into the enclosed volume 22 as the reactor 16 consumes a selected gas within the enclosed volume thus reducing gas pressure within the enclosed volume.
- the reactor housing element 14 could also be made from materials that are impervious to particular gasses (e.g., oxygen) and pervious to other gases (e.g., nitrogen).
- the reactor housing element 14 can be formed of a material that is at least partially gas permeable for selected gasses (e.g., nitrogen gas permeable) to exhaust the selected gas from the tissue site 20 to atmosphere.
- the reactor housing element 14 includes a lower surface 56 .
- An adhesive 58 (depicted schematically in FIG. 2 ) can be applied to the lower surface 56 .
- the lower surface 56 contacts the skin around the tissue site 20 and the adhesive 58 adheres the reactor housing element 14 to the skin around the tissue site 20 .
- a reactor housing element gasket 60 which can be a hydrogel gasket similar to the skin contacting gasket 36 described above, can be provided between the lower surface 56 of the reactor housing element 14 and the skin to further seal between the reactor housing element 14 and the skin to preclude air migration between the interface between the lower surface 56 the skin.
- the reactor housing element 14 can affix to the interface side 32 of the skin contacting element 24 providing a substantially air-tight seal between the reactor housing element 14 and the skin contacting element 24 .
- the adhesive 58 applied to the lower surface 56 can affix the reactor housing element 14 to the skin contacting element 24 .
- the reactor housing element gasket 60 can be provided between the lower surface 56 of the reactor housing element 14 and the interface side 32 of the skin contacting element 24 to further seal between the reactor housing element 14 and the skin contacting element 24 to preclude air migration between the interface between the lower surface 56 of the reactor housing element 14 and the interface side 32 of the skin contacting element 24 .
- the reactor 16 is positioned in the enclosed volume 22 and is configured to react with one of more selected gases (e.g., nitrogen, oxygen, carbon dioxide) found in air to consume the selected gas within the enclosed volume 22 , which can reduce gas pressure within the enclosed volume 22 .
- the reduction in gas pressure within the enclosed volume 22 can result in a partial vacuum being formed in the enclosed volume 22 , which can result in a downward force (in the direction of arrow 70 ) being applied to the hood 50 of the reactor housing element 14 .
- the reactor housing element 14 can be configured such that the downward force (in the direction of arrow 70 ) on the hood 50 (or the top of the reactor housing element 14 ) results in an outward force (normal to the direction of arrow 70 ) on the lower peripheral section 52 .
- the reactor housing element 14 is affixed to the skin contacting element 24 , which is adhered to the subject's skin, or directly to the skin (see FIG. 1 ) the outward force in the direction normal to arrow 70 can result in small strains and stresses being applied to the patient's skin around the tissue site 20 . These strains and stresses being applied to the patient's skin can be beneficial for the introduction of the cosmetic liquid or cream impregnated within the cosmetic pad 18 as well as providing a massaging effect of the skin.
- reactor housing element 14 is made from a relatively more rigid material with respect to the skin contacting element 24
- flexible regions 74 can be provided in the lower peripheral section 52 to facilitate outward movement of the reactor housing element 14 with respect to the tissue site 20 to allow for the small strains and stresses to be applied to the subject's skin at the tissue site 20 .
- the reactor 16 is positioned in the enclosed volume 22 and is configured to react with the selected gas (e.g., nitrogen, oxygen, carbon dioxide) found in air. As the reactor 16 consumes the selected gas within the enclosed volume 22 , the gas pressure within the enclosed volume 22 is reduced. For example, where the reactor 16 consumes oxygen, there can be an approximate 20% reduction from atmospheric pressure in the enclosed volume 22 .
- the selected gas e.g., nitrogen, oxygen, carbon dioxide
- the reactor 16 can be used in the controlled pressure device.
- US 2014/0109890 A1 describes an oxygen based heater; however, the oxygen based heater described in US 2014/0109890 A1 can be used as the reactor 16 to consume oxygen within the enclosed volume 22 thus producing a partial vacuum within the enclosed volume 22 .
- the reactor 16 includes a reducing agent, a binding agent on a reactor substrate 80 and an electrolyte solution, which can be provided in an electrolyte impregnated pad 82 .
- the reducing agent on the reactor substrate 80 can be zinc, aluminum, or iron, for example.
- the release layer 40 can operate as an air-tight barrier such that the selected gas (e.g., nitrogen, oxygen, carbon dioxide) is precluded from access to the reactor 16 until after the air-tight barrier, which in this instance is the release layer 40 , is removed from the controlled pressure device 10 .
- the controlled pressure device 10 can include a package, which is shown in FIG. 2 as including an upper layer 94 and a lower layer 96 .
- the upper layer 94 affixes to the lower layer 96 enclosing the reactor substrate 80 in between the upper layer 94 and the lower layer 96 so as to provide an air-tight seal so that the selected gas is precluded from access to the reactor 16 .
- the upper layer 94 or the lower layer 96 can operate as an air tight barrier in that removal of the upper layer 94 from the lower layer 96 , or vice versa, allows the selected gas access to the reactor 16 so that the selected gas can be consumed by the reactor 16 .
- at least one of the layers can include openings 98 and a seal layer 102 can be affixed in an air-tight manner to the lower layer 96 covering the openings 98 . Removal of the seal layer 102 from the lower layer 96 exposes the reactor 16 to the selected gas, which allows the reactor to consume the selected gas within the enclosed volume 22 .
- the surface area of the openings 98 can be appropriately sized to control the flow of the selected gas through the openings to sustain the chemical reaction of the reactor 16 to the desirable time limit for maintaining topical negative pressure on the tissue site 20 for the desired duration.
- multiple seal layers 102 can be provided so that removal of one or a selected few of the seal layers (while other seal layers are still affixed to the lower layer 96 ) can also be provided to limit the flow of the selected gas toward the reactor 16 .
- the controlled pressure device 10 can include a pressure relief valve 106 on the reactor housing element 14 .
- the pressure relief valve 106 can allow for selected communication between the enclosed volume 22 and ambient.
- the pressure relief valve 106 can be operated when a predetermined pressure differential exists between the enclosed volume 22 and ambient.
- the pressure relief valve 106 can be configured to open when the temperature within the enclosed volume exceeds a desired predetermined temperature.
- the controlled pressure device 10 can be configured to allow an operator to change the size of the enclosed volume 22 while the reactor 16 consumes the selected gas in the enclosed volume, thus varying the gas pressure within the enclosed volume 22 .
- a tab 110 can be affixed to the reactor housing element 14 , and the operator can pull the tab 110 to move the reactor housing element away from the tissue site 20 .
- the tab 110 is affixed to the hood 50 .
- the hood 50 will tend to travel toward the tissue site 20 .
- the hood 50 can be moved away from the tissue site 20 and air can enter the enclosed volume 22 , for example by leaking past the gasket 36 or a small pre-configured leakage path can be provided. Air entering the enclosed volume 22 can increase the pressure within the enclosed volume 22 until the selected gas (e.g., oxygen) is consumed by the reactor 16 . Such a configuration can allow for a cycling of pressure in the enclosed volume 22 .
- the selected gas e.g., oxygen
- the controlled pressure device 10 can also be packaged such that the reactor housing element 14 and the reactor 16 are packaged separately from the skin contacting element 24 , for example.
- a reactor housing element release layer 120 can be provided.
- the reactor housing element 14 release layer 120 can be similar to the release layer 40 having an upper side 122 that is releasable from the lower surface 56 of the reactor housing element 14 .
- the reactor housing element release layer 120 further includes a lower surface 124 that is opposite to the upper side 122 .
- the reactor housing element release layer 120 can also be affixed to the lower layer 96 , so that removal of the reactor housing element release layer 120 from the reactor housing element 14 results in removal of the lower layer 96 from the upper layer 94 , thus exposing the reactor 16 to air.
- the reactor housing element release layer 120 can be affixed to the seal layer 102 such that removal of the reactor housing element release layer 120 from the reactor housing element 14 results in removal of the seal layer 102 from the lower layer 96 , thus exposing the reactor 16 to air via the openings 98 provided in the lower layer 96 .
- an upper skin contacting element release layer (not shown) can be provided.
- the upper skin contacting element release layer can be similar to the release layer 40 .
- no upper skin contacting element release layer need be provided.
- the controlled pressure device 10 further includes a liquid impermeable-air permeable membrane 150 interposed between the reactor 16 and the cosmetic liquid or cream, which is impregnated in the cosmetic pad 18 in the illustrated embodiment.
- the size (area) of the liquid impermeable-air permeable membrane 150 can depend on the location of the liquid impermeable-air permeable membrane 150 within the controlled pressure device 10 . If the cosmetic liquid or cream were to come in contact with the reactor 16 , the chemical reaction of the reactor 16 when coming in contact with the selected gas may be detrimentally impacted. As such, the liquid impermeable-air permeable membrane 150 allows air flow within the enclosed volume 22 while precluding the cosmetic liquid or cream from coming into contact with the reactor 16 .
- the liquid impermeable-air permeable membrane 150 can be located in different locations on the controlled pressure device 10 .
- the liquid impermeable-air permeable membrane 150 can be located between the reactor substrate 80 and the lower layer 96 making up the air-tight package for the reactor 16 . So, once the lower layer 96 (or the seal layer 102 ) is removed, air can gain access to the reactor 16 , but the cosmetic liquid or cream would be precluded from traveling through the liquid impermeable-air permeable membrane 150 .
- the liquid impermeable-air permeable membrane 150 can be located between the lower layer 96 (or the seal layer 102 ) making up the air-tight package for the reactor 16 and the cosmetic liquid or cream, which can be impregnated in the cosmetic pad 18 . More generally, and as depicted in FIG. 1 , the liquid impermeable-air permeable membrane 150 can be located between the reactor 16 and the cosmetic liquid or cream, which would be impregnated in the cosmetic pad 18 . As depicted in FIG.
- the liquid impermeable-air permeable membrane 150 can be connected with the reactor housing element 14 and preclude the cosmetic liquid or cream from passing through the liquid impermeable-air permeable membrane 150 while allowing air to travel through the liquid impermeable-air permeable membrane 150 so that the selected gas can be removed from the enclosed volume 22 .
- the liquid impermeable-air permeable membrane 150 could surround the reactor 16 and preclude the cosmetic liquid or cream from passing through the liquid impermeable-air permeable membrane 150 while allowing air to travel through the liquid impermeable-air permeable membrane 150 .
- the release layer 40 can be removed from the skin contacting element 24 .
- the skin contacting element 24 can be pressed against a subject's skin around the tissue site 20 and adhesive 38 on the skin contacting side of the skin contacting element 24 can adhere the skin contacting element 24 to the subject's skin.
- the skin contacting gasket 36 can surround the tissue site 20 to promote an air-tight seal between the skin contacting element 24 and the subject's skin around the tissue site 20 .
- the cosmetic liquid or cream which is located within the cosmetic pad 18 in the illustrated embodiment, is then brought into contact with the tissue site 20 by traveling through the openings 34 .
- the reactor housing element release layer 120 can be removed from the reactor housing element 14 . Removal of the reactor housing element release layer 120 from the reactor housing element 14 can expose the reactor 16 to air by removal of the lower layer 96 , the seal layer 102 , or the reactor housing element release layer 120 may be affixed in an air-tight manner to the reactor housing element 14 so that air is precluded from access to the reactor 16 until after the reactor housing element release layer 120 is removed from the reactor housing element 14 .
- the lower surface 56 of the reactor housing element 14 can be brought in contact with an upper surface 152 of the liquid impermeable-air permeable membrane 150 , which can have its lower surface 154 affixed to the interface side 32 of the skin contacting element 24 .
- the lower surface 56 of the reactor housing element 14 can be brought in contact with the interface side 32 of the skin contacting element 24 .
- the reactor 16 consumes the selected gas found within the enclosed volume 22 .
- a chemical reaction occurs where heat can be generated, and a pressure reduction with respect to atmospheric pressure occurs by consumption of the selected gas.
- the reactor 16 can heat the enclosed volume 22 above ambient, which can provide a therapeutic effect for use with some cosmetic liquids or creams.
- suction can be applied to the tissue site thus stretching the subject's skin at the tissue site, which can also have a therapeutic effect with certain cosmetic liquids or creams.
- the application of topical negative pressure at a particular tissue site can also have a therapeutic effect.
- the controlled pressure device 10 can be designed with certain parameters. As an example, assuming the tissue site 20 of about 10 cm ⁇ 20 cm and an offset of the hood 50 (or the top of the reactor housing element 14 ) of about 2.5 cm from the tissue site 20 results in the enclosed volume 22 of 500 mL. Assuming that the cosmetic liquid or cream and the solid components of the cosmetic pad 18 in addition to the reactor 16 and any other solid components (e.g., the liquid impermeable-air permeable membrane 150 ) within the enclosed volume 22 account for 100 mL within the enclosed volume 22 , this leaves 400 mL air in the enclosed volume.
- leakage past interfaces e.g., leakage around the skin contacting gasket 36
- diffusion e.g., diffusion through the reactor housing element 14
- leakage The gaskets 36 , 60 , the skin contacting element 24 and reactor housing element 14 are configured to have a maximum leakage rate of air into the enclosed volume 22 from ambient. For example, a maximum leakage rate of 1 mL (STP)/hour of air into the enclosed volume from ambient results in 0.2 mL (STP) of oxygen/hour.
- 1 g of zinc consumes 170 mL of oxygen (STP)
- 1 g of zinc provides an adequate amount of a reducing agent to result in a 20% reduction from normal atmospheric pressure within the enclosed volume 22 for an extended period of time, e.g., well over 72 hours.
- the controlled pressure device 10 will likely be worn for a much shorter period of time and the tissue site 20 being treated may be much smaller than 10 cm ⁇ 20 cm. It can be seen that a very small reactor 16 , e.g., one able to accommodate less than 1 g of zinc, can be used in the controlled pressure device 10 .
- the controlled pressure device 10 can be configured as follows.
- the reactor 16 can be configured to have a predetermined scavenging capacity (“SC”), which relates to the volume of the selected gas that the reactor 16 is configured to consume.
- SC scavenging capacity
- 1 g of zinc will consume about 170 mL of oxygen (STP), so the scavenging capacity would be 170 mL.
- the enclosed volume 22 can have a determined volume (“DV”) based on the area of the tissue site 20 , the size of the reactor housing element 14 , the offset of the hood 50 (or top of the reactor housing element 14 ) from the tissue site 20 , taking into account the cosmetic liquid or cream and the solid components of the cosmetic pad 18 in addition to the reactor 16 and any other solid components within the enclosed volume 22 .
- the determined volume of 400 mL was discussed above.
- the controlled pressure device 10 can be configured to have a maximum leakage rate (LR) for air entering the enclosed volume 22 .
- the controlled pressure device 10 can be configured to have a minimum wear time (“MWT”), which relates to the minimum amount of time that the controlled pressure device 10 is configured to be worn. Assuming that it is desirable to have the reactor 16 consume, or scavenge, the selected gas for the entire minimum wear time, the controlled pressure device can be configured in view of the following relationship:
- the scavenging capacity can be determined to provide a relatively small reactor 16 in relation to the reactor housing element 14 and the tissue site 20 to be treated.
- the determined volume can be determined to provide a relatively small reactor 16 and reactor housing element 14 in view the tissue site 20 to be treated.
- the maximum leakage rate for air entering the enclosed volume 22 should be reduced as much as is practical; however, there may be some circumstances in which a predetermined amount of leakage is desirable, for example where cycling of pressure within the enclosed volume 22 is desired.
- the maximum leakage rate for air entering the enclosed volume 22 can be less than 10 mL/hour, and preferably less than 1 or 2 mL/hr.
- the minimum wear time can be determined based on the desired amount of time the topical negative pressure is to be applied to the tissue site 20 . It may be desirable to include a safety factor (e.g., a multiplier on the right side of the relationship above) to accommodate for manufacturing tolerances, differences among tissues sites and subjects placing the controlled pressure device 10 on the tissue site 20 .
- the reactor 16 consumes the selected gas found in air within the enclosed volume 22 , an exothermic reaction occurs such that there is an increase in temperature of the reactor 16 .
- the reactor 16 can operate as a heater to heat the cosmetic liquid or cream impregnated in the cosmetic pad 18 . This can change the viscosity of the cosmetic liquid or cream, which can facilitate entry of the cosmetic liquid or cream into skin pores.
- the reactor housing element 14 could also be provided with a removable section 160 that when removed could provide ambient air access to the reactor 16 or an additional reactor located beneath the reactor housing element 14 .
- the removable section 160 can be affixed to the upper layer 94 of the package in which the reactor substrate 80 is located. Removal of the removable section 160 can result in removal of at least a portion of the upper layer 94 thus exposing the reactor substrate 80 to ambient air, which would result in an exothermic reaction.
- an additional reactor could be located beneath the reactor housing element 14 and removal of the removable section 160 can result in removal of at least a portion of the package (similar to the package made up of the upper layer 94 and the lower layer 96 ) thus exposing the additional reactor to ambient air.
- the additional reactor can also heat the gas in the enclosed volume 22 , which can heat the tissue site 20 .
- FIG. 3 depicts multiple reactor substrates or multiple regions on the same reactor substrate, which are depicted as reactor elements 80 a , 80 b and 80 c each having different chemical properties and/or characteristics.
- the first reactor element 80 a can be configured to begin consuming oxygen after being exposed to oxygen for a very short (first) period of time t 1 , e.g., nearly instantaneously.
- the second reactor element 80 b can be configured to begin consuming oxygen after being exposed to oxygen for a longer (second) period of time t 2
- the third reactor element 80 c can be configured to begin consuming oxygen after being exposed to oxygen for an even longer (third) period of time.
- the second reactor element 80 b can be configured with a delayed reaction time to begin consuming oxygen after the first reactor element 80 a has been exhausted and no longer consumes oxygen.
- the third reactor element 80 c can be configured with a delayed reaction time to begin consuming oxygen after the first reactor element 80 a and the second reactor element 80 b have both been exhausted and no longer consume oxygen.
- Such a configuration can allow for a cycling of pressure in the enclosed volume 22 .
- the reactor 16 may be one or any combination of a zinc-based chemical pump, electro-chemical pumps, vacuum-on-demand devices (referred to herein as VOD), electrolyzers, pressure-reducing solid state devices, oxygen absorbing iron packets, or getters of zirconium titanium, vanadium iron, lithium, lithium metal, magnesium, calcium, lithium barium combinations, zinc-air battery, zinc-air battery components or other materials highly reactive with the selected gases, for example, nitrogen, carbon dioxide and oxygen gases found in skin tissue environments.
- VOD vacuum-on-demand devices
- electrolyzers pressure-reducing solid state devices
- oxygen absorbing iron packets or getters of zirconium titanium, vanadium iron, lithium, lithium metal, magnesium, calcium, lithium barium combinations
- zinc-air battery zinc-air battery components or other materials highly reactive with the selected gases, for example, nitrogen, carbon dioxide and oxygen gases found in skin tissue environments.
- FIG. 4 depicts another reactor 226 that can be used in place of the reactor 16 shown in FIG. 1 .
- WO 2015/054040 A1 which is incorporated by reference, describes an electrochemical cell that is adapted to consume gases, i.e., air or its gaseous non-noble constituents, within an enclosure via an electrochemical reaction. This consumption of gas within a sealed enclosure forms a partial vacuum.
- the controlled pressure device 10 can include such a reactor 226 having an electrochemical cell 228 that lowers the pressure within the enclosed volume 22 through an electrochemical reaction that takes place when a voltage is applied to the electrochemical cell 228 by a power source 230 (depicted schematically in FIG. 4 ).
- Operation of electrochemical cell 228 in this example can also be achieved by controlling the current supplied to the electrochemical cell 228 by the power source 230 , for example by providing a switch 232 that can be operated by the user.
- the power source 230 can be located in the enclosed volume 22 or be provided outside the controlled pressure device 10 (e.g. on the reactor housing element 14 ).
- the switch 232 can be provided outside the controlled pressure device 10 (e.g. on the reactor housing element 14 ).
- a VOD is a solid state electrochemical cell, which when charged with a low voltage, produces a highly reactive material that captures gases present in the atmosphere and when sealed in an air tight system can form a partial vacuum.
- metal is deposited to grow dendrites as a voltage is applied across electrodes of the VOD device and lithium salt electrolyte, charging the VOD device. Similar to charging a battery, electrons are moved from layer to layer to form metallic lithium.
- a getter is a deposit of reactor material that is used for initiating and maintaining a partial vacuum.
- gas molecules strike the getter material particular gas molecules (i.e., those of the selected gas) combine with the getter chemically or by adsorption.
- the getter removes the selected gas from the evacuated space until the active material is exhausted.
- a reactor having a self-regulating oxygen getter powered by zinc-air battery technology may be used in lieu of the above-described reactor 16 made up of the reactor substrate 80 .
- Zinc-air batteries can react to control or reduce the oxygen levels in sealed site and thus self-regulate a reduced pressure of approximately 0.8 bars. If the zinc-air battery components are configured as a working zinc-air battery, the battery voltage will drop when the oxygen has been depleted and the desired partial vacuum pressure will have been achieved. This drop in voltage may be used to indicate that the desired partial vacuum has been achieved.
- a 675 size hearing aid zinc-air battery is rated at 620 mAh, occupies 0.5 mL volume, and weighs 1.9 g.
- a 675 zinc-air battery can remove more than 150 times its volume of oxygen.
- the cosmetic pad 18 can be made from a blend of polyester and cellulose fibers, polypropylene fibers, or other suitable non-woven polymeric material.
- the cosmetic liquid or cream can include at least one of a moisturizer, dimethylaminoethanol (DMAE), Acetyl hexapeptide-8, Acetyl hexapeptide-3, retinol, ubiquinone, dithiolane-3-pentanic acid, alpha-hydroxy acid, alpha lipoic acid, salicylic acid, hydrocortisone, topical botulinum cream, and hyaluronic acid.
- the cosmetic pad 18 can include top surface 180 and a bottom surface 182 , which is opposite the top surface 180 .
- the bottom surface 182 can be undulated having hills 184 and valleys 186 , which can allow the cosmetic pad 18 to act as a skin massaging element.
- An additional membrane 188 could be provided and located beneath the cosmetic pad 18 to act as the skin massaging element. This additional membrane 188 would also be positioned adjacent to the tissue site 20 . This additional membrane 188 could also include an undulated bottom surface, similar to the bottom surface 182 having hills 184 and valleys 186 . This additional membrane 188 would also include openings to allow the cosmetic liquid or cream to pass through the openings to the tissue site 20 .
- a partial vacuum is provided in the enclosed volume 22 , the skin can be drawn towards the undulated surface and the skin can conform to the hills 184 and valleys 186 . Accordingly, small strains and stresses can applied to the patient's skin at the tissue site 20 providing a massaging effect.
- the controlled pressure device 10 can also include additional powered components, which is shown as a powered component 240 that is schematically depicted in FIG. 2 .
- Each powered component 240 which are described later with reference to FIGS. 5-7 , can be electrically connected with a power source 242 (depicted schematically in FIG. 2 ) which, for example, can be a zinc-air battery exposed to ambient or a zinc MnO2 battery, electrically connected with the powered component 240 .
- the power source 242 When using a zinc-air battery as the power source 242 , the power source 242 would be located outside of the enclosed volume 22 or a section of the reactor housing element 14 or the skin contacting element 24 could be removable to allow ambient air to contact the zinc-air battery.
- FIG. 5 depicts a heater 250 , which is one example of a powered component 240 that can be used in the controlled pressure device 10 , electrically connected with the power source 242 .
- the heater 250 can be a thin film heater or thin film nano wire heater.
- the heater 250 can heat the cosmetic liquid or cream impregnated in the cosmetic pad 18 .
- the heater 250 can be positioned adjacent to the cosmetic pad 18 .
- a switch 252 can be provided to control power to the heater 250 .
- the heater 250 can also heat the gas in the enclosed volume 22 , which can heat the tissue site 20 .
- FIG. 6 depicts a first electrode 260 and a second electrode 262 electrically connected with the power source 242 .
- the electrodes are another example of a powered component 240 that can be used in the controlled pressure device 10 .
- the switch 252 can be provided to control power to the electrodes 260 , 262 .
- the first electrode 260 can be positioned on a first side of the tissue site 20 and in contact with the skin, and the second electrode 262 can be positioned on a second, opposite, side of the tissue site 20 and in contact with the skin.
- the electrodes 260 , 262 can be used to provide electrical stimulation to the tissue site 20 .
- FIG. 7 depicts a light source 280 , which is another example of a powered component 240 that can be used in the controlled pressure device 10 .
- the light source 280 can include a plurality of LEDs 282 mounted on a flexible substrate 284 .
- the LEDs 282 are electrically connected with the power source 242 .
- the flexible substrate 284 can be placed adjacent to the skin contacting element 24 , which can include larger openings 34 , which can allow light to pass for phototherapy.
- FIG. 8 depicts a method of treating tissue using negative pressure. Although the FIG. 8 shows a specific order of method steps, the order of the steps may differ from what is depicted. Also two or more steps may be performed concurrently or with partial concurrence. The method will be described with reference to the controlled pressure device 10 depicted in FIGS. 1 and 2 , however, the method can be practiced with other devices.
- the reactor housing element release layer 120 is removed from the reactor housing element 14 . Removal of the reactor housing element release layer 120 from the reactor housing element 14 can allow air to contact the reactor 16 , which can begin the reaction in which oxygen (or another selected gas in air) is being consumed by the reactor 16 .
- the reactor housing element 14 , the reactor 16 and the liquid impermeable—air permeable membrane 150 are placed over the tissue site 20 .
- the reactor housing element 14 is affixed with respect to the skin around the tissue site 20 to define an at least substantially air-tight enclosed volume 22 around the tissue site. The reactor 16 can consume the selected gas (e.g., oxygen) from the enclosed volume 22 thus reducing the gas pressure in the enclosed volume 22 .
- FIG. 9 depicts other steps in a method of treating tissue using negative pressure.
- the method may include, at 310 , placing a cosmetic liquid or cream on the tissue site 20 .
- the cosmetic liquid or cream may be placed on the tissue site 20 prior to placing the reactor housing element 14 , the reactor 16 and the liquid impermeable—air permeable membrane 150 over the tissue site 20 , which occurs at step 302 .
- the method of treating tissue using negative pressure may also include, at 312 , placing a pad 18 impregnated or wetted with a cosmetic liquid or cream over the tissue site 20 .
- the pad 18 can be connected with the reactor housing element 14 in such a manner that the pad 18 is placed on the tissue site 20 while placing the reactor housing element 14 , the reactor 16 and the liquid impermeable—air permeable membrane 150 over the tissue site 20 .
- the method of treating tissue using negative pressure may also include, at 314 , removing the release layer 40 from the skin contacting element 24 , and, at 316 , placing the skin contacting element 24 over or around the tissue site 20 .
- the skin contacting element 24 can be placed over or around the tissue site 20 prior to placing the reactor housing element 14 , the reactor 16 and the liquid impermeable—air permeable membrane 150 over the tissue site 20 , which occurs at step 302 .
- affixing the reactor housing element 14 with respect to skin around the tissue site, which occurs at step 304 can further include affixing the reactor housing element 14 to the skin contacting element 24 , at 318 .
- the method may also include affixing the skin contacting element 24 to the skin around the tissue site 20 , at 320 .
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Rehabilitation Therapy (AREA)
- Biophysics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Otolaryngology (AREA)
- Medical Informatics (AREA)
- Dermatology (AREA)
- Pathology (AREA)
- Surgical Instruments (AREA)
- Cosmetics (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Materials For Medical Uses (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Pulmonology (AREA)
- Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- This application claims priority to U.S. Provisional Application Ser. No. 62/248,422 filed on Oct. 30, 2015, the entirety of which is expressly incorporated by reference.
- The pores of the skin can become occluded with impurities. Negative pressure has been used to generate a partial vacuum to aid in removing impurities from the pores. Negative pressure is a term used to describe a pressure that is below normal atmospheric pressure. At room temperature and at sea level, a defined volume of air contains molecules moving in random directions, and these moving molecules exert a force that is equal to the normal atmospheric pressure of approximately 760 mmHg (about 1 bar). Negative pressure has been achieved by removing air from an area of interest, for example at a tissue site via a suction pump.
- Devices for the generation of topical negative pressure at the surface of a person's skin have been used for many hundreds of years to treat humans. For example, the cupping technique, which relates to positioning a mouth of a rigid vessel containing hot air on a human's skin, is a well-known technique. Spring powered syringes and suction cups are other mechanical techniques that have been used for generating a partial vacuum on human tissue. In common with cupping, such other mechanical techniques have offered a limited topical negative pressure duration and little or no range of neutral to positive pressures. This is due to design constraints and that the cupping technique and other mechanical techniques are not self-contained and can hinder a user's mobility.
- To enable a more prolonged application of topical negative pressure, powered systems, which include a vacuum generation source such as a pump, have been developed and many examples of such systems are used today for skin treatments and restorative purposes like the temporary removal of wrinkles. Many of these systems, however, are not convenient for users. Such known systems can be large, heavy, noisy, uncomfortable, and not simple for users to apply and initiate a controlled pressure condition. Such known systems also rely on an outside power or vacuum source to create topical negative pressure conditions.
- In view of the foregoing, a controlled pressure device includes a reactor housing element and a reactor. The reactor housing element is configured to at least partially define an at least substantially air-tight enclosed volume around a tissue site when fixed in space in relation to the tissue site. The reactor is positioned in the enclosed volume and is configured to react with a selected gas found in air. The reactor consumes the selected gas within the enclosed volume.
- Another example of a controlled pressure device can include a reactor housing element and a reactor. The reactor housing element is configured to at least partially define an at least substantially air-tight enclosed volume around a tissue site when fixed in space in relation to the tissue site, and the enclosed volume has a determined volume (DV). The reactor is positioned in the enclosed volume and is configured to react with a selected gas found in air. The reactor consumes the selected gas within the enclosed volume. The reactor is configured having a predetermined scavenging capacity (SC) for the selected gas. The controlled pressure device is configured to have a maximum leakage rate (LR) when affixed to a subject's skin for air entering the enclosed volume. The controlled pressure device is also configured to a minimum wear time (MWT) and is configured according to the following relationship: SC>DV*(% of selected gas in air)+LR*(% of selected gas in air)*MWT.
- In view of the foregoing, method of treating a tissue site includes removing a release layer from a reactor housing element. The method further includes placing the reactor housing element, a reactor and a liquid impermeable—air permeable membrane over the tissue site. The method also includes affixing the reactor housing element with respect to skin around the tissue site to define an at least substantially air-tight enclosed volume around the tissue site.
-
FIG. 1 is a schematic cross-sectional view of a controlled pressure device. -
FIG. 2 is a schematic exploded perspective view of a controlled pressure device. -
FIGS. 3 and 4 are schematic depictions of alternative reactor embodiments that can be used with the controlled pressure device shown inFIG. 1 . -
FIGS. 5-7 are schematic depictions of powered components that can be used with the controlled pressure device shown inFIG. 1 . -
FIGS. 8 and 9 are flow diagrams depicting a method of treating a tissue site. -
FIG. 1 depicts a controlledpressure device 10 including areactor housing element 14 and areactor 16. The controlledpressure device 10 can be used in conjunction with a cosmetic liquid or cream for tissue treatment. For example, the controlledpressure device 10 can include or be used in conjunction with a pad, which can be wetted or impregnated with a cosmetic liquid or cream, and will be hereinafter referred to as acosmetic pad 18. The controlledpressure device 10 can be positioned at atissue site 20 to enhance tissue treatment including, but not limited to, wound healing, reduction of skin wrinkles, and other skin maladies. Thereactor housing element 14 is configured to at least partially define an at least substantially air-tight enclosedvolume 22 around thetissue site 20 when affixed in space in relation to thetissue site 20.FIG. 1 depicts thereactor housing element 14 in contact with the tissue (e.g., skin) around thetissue site 20, however, thereactor housing element 14 can be fixed in space in relation to thetissue site 20 without being in direct contact with the tissue around thetissue site 20. For example, an intermediate membrane or layer, such as a skin contacting element 24 (FIG. 2 ), could be interposed between thereactor housing element 14 and the tissue (e.g., skin) around thetissue site 20, although thereactor housing element 14 is fixed in space in relation to thetissue site 20. Thereactor 16 positioned in the enclosedvolume 22 reacts with a selected gas found in air and consumes the selected gas within the enclosedvolume 22. The cosmetic liquid or cream is also located in the enclosedvolume 22. - With reference to
FIG. 2 , the controlledpressure device 10 can includes theskin contacting element 24. Theskin contacting element 24 includes askin contacting side 30 that is adherable to a subject's skin and aninterface side 32, which is opposite to the skin contacting side. In the illustrated embodiment, theskin contacting element 24 is shown as a separate element from thereactor housing element 14. In an alternative arrangement, theskin contacting element 24 can be provided as part of thereactor housing element 14, e.g., theskin contacting element 24 can be integrally formed with thereactor housing element 14 or connected with thereactor housing element 14 at the manufacturing facility. Theskin contacting element 24 can be made from a thin sheet-like membrane, for example using a roll-to-roll process. In the illustrated embodiment, theskin contacting element 24 also includesopenings 34 extending through theskin contacting element 24 from theskin contacting side 30 to theinterface side 32. Theopenings 34 can be located over thetissue site 20. In conjunction with askin contacting gasket 36, theskin contacting element 24 is configured to provide a seal around thetissue site 20 to allow for topical negative pressure to be applied at thetissue site 20. If desired, theskin contacting element 24 can include an opening that is larger than each of theopenings 34 depicted inFIG. 2 . In this example, theopening 34 can be dimensioned to fit around thetissue site 20. The opening 34 in this example can be similarly shaped to thecosmetic pad 18 so that theskin contacting element 24 and theskin contacting gasket 36 provide a seal around the tissue site 20 (FIG. 1 ) and thecosmetic pad 18. If desired, theskin contacting element 24 need not include the opening(s) 34, and in this example, thecosmetic pad 18 can be positioned beneath theskin contacting side 30 so as to come in contact with the subject's skin at thetissue site 20. - Both the
skin contacting side 30 and theinterface side 32 are generally flat or planar. In the illustrated embodiment, theinterface side 32 is the upper side of theskin contacting element 24 and theskin contacting side 30 is the lower side of the skin contacting element. Adhesive 38 (depicted schematically inFIG. 2 ) can provided on theskin contacting side 30 to allow theskin contacting side 30 to adhere to the subject's skin around thetissue site 20. - The
skin contacting gasket 36 can be provided on theskin contacting side 30 of theskin contacting element 24 or simply be positioned between theskin contacting side 30 and the subject's skin. Theskin contacting gasket 36 can be made from a hydrogel to further promote sealing around thetissue site 20 to promote the topical negative pressure at thetissue site 20. - A
release layer 40 can be provided with the controlledpressure device 10 to protect theskin contacting side 30 of theskin contacting element 24. Therelease layer 40 can be similar to known release layers and include anupper side 42 that is releasable from theskin contacting side 30 of theskin contacting element 24. Therelease layer 40 also includes alower surface 44 opposite theupper side 42. As mentioned above, thereactor 16 reacts with a selected gas found in air and consumes the selected gas within theenclosed volume 22. In some embodiments, therelease layer 40 can provide an air-tight barrier such that air is precluded from access to thereactor 16 until after therelease layer 40 is removed from theskin contacting element 24. In embodiments where theskin contacting element 24 may not be provided, therelease layer 40 can cooperate with thereactor housing element 14 in a similar manner, and therelease layer 40 can provide an air-tight barrier such that air is precluded from access to thereactor 16 until after therelease layer 40 is removed from thereactor housing element 14. - With reference back to
FIG. 1 , thereactor housing element 14 at least partially defines theenclosed volume 22 around thetissue site 20 when fixed in space in relation to thetissue site 20. With reference to the embodiment depicted inFIG. 2 , thereactor housing element 14 cooperates with theskin contacting element 24 to at least partially define the enclosed volume 22 (seeFIG. 1 ) around thetissue site 20, for example, when theskin contacting side 30 of theskin contacting element 24 is in contact with and adhered to the subject's skin and thereactor housing element 14 is affixed to theskin contacting element 24. Thereactor housing element 14 can be formed with ahood 50 and a lowerperipheral section 52 that at least partially surrounds thehood 50. In the illustrated embodiment, the lowerperipheral section 52 entirely surrounds thehood 50, which is raised in relation to the lowerperipheral section 52 so as to define theenclosed volume 22 around thetissue site 20. Thereactor housing element 14 can also be formed without thehood 50, i.e., thereactor housing element 14 could initially be planar. Similar to theskin contacting element 24, thereactor housing element 14 can be made from a thin sheet-like membrane, for example using a roll-to-roll process. Thereactor housing element 14 can be made from a flexible material that is similar to or the same flexibility as theskin contacting element 24, which allows the controlledpressure device 10 to conform to the skin around thetissue site 20. When thereactor housing element 14 is affixed to theskin contacting element 24, thereactor 16 is located between thereactor housing element 14 and thecosmetic pad 18 and theskin contacting element 24. Since thereactor housing element 14 is made from a flexible material in this example, the section of thereactor housing element 14 that is not in contact with theskin contacting element 24 is raised or offset from thetissue site 20 so as to form thehood 50. - The
reactor housing element 14 can be made from a material that is air impermeable so that air is precluded or greatly inhibited from entering into theenclosed volume 22 as thereactor 16 consumes a selected gas within the enclosed volume thus reducing gas pressure within the enclosed volume. Thereactor housing element 14 could also be made from materials that are impervious to particular gasses (e.g., oxygen) and pervious to other gases (e.g., nitrogen). Thereactor housing element 14 can be formed of a material that is at least partially gas permeable for selected gasses (e.g., nitrogen gas permeable) to exhaust the selected gas from thetissue site 20 to atmosphere. Thereactor housing element 14 includes alower surface 56. An adhesive 58 (depicted schematically inFIG. 2 ) can be applied to thelower surface 56. With reference toFIG. 1 , thelower surface 56 contacts the skin around thetissue site 20 and the adhesive 58 adheres thereactor housing element 14 to the skin around thetissue site 20. A reactorhousing element gasket 60, which can be a hydrogel gasket similar to theskin contacting gasket 36 described above, can be provided between thelower surface 56 of thereactor housing element 14 and the skin to further seal between thereactor housing element 14 and the skin to preclude air migration between the interface between thelower surface 56 the skin. - With reference to
FIG. 2 , thereactor housing element 14 can affix to theinterface side 32 of theskin contacting element 24 providing a substantially air-tight seal between thereactor housing element 14 and theskin contacting element 24. The adhesive 58 applied to thelower surface 56 can affix thereactor housing element 14 to theskin contacting element 24. The reactorhousing element gasket 60 can be provided between thelower surface 56 of thereactor housing element 14 and theinterface side 32 of theskin contacting element 24 to further seal between thereactor housing element 14 and theskin contacting element 24 to preclude air migration between the interface between thelower surface 56 of thereactor housing element 14 and theinterface side 32 of theskin contacting element 24. - The
reactor 16 is positioned in theenclosed volume 22 and is configured to react with one of more selected gases (e.g., nitrogen, oxygen, carbon dioxide) found in air to consume the selected gas within theenclosed volume 22, which can reduce gas pressure within theenclosed volume 22. The reduction in gas pressure within theenclosed volume 22 can result in a partial vacuum being formed in theenclosed volume 22, which can result in a downward force (in the direction of arrow 70) being applied to thehood 50 of thereactor housing element 14. Thereactor housing element 14 can be configured such that the downward force (in the direction of arrow 70) on the hood 50 (or the top of the reactor housing element 14) results in an outward force (normal to the direction of arrow 70) on the lowerperipheral section 52. Since thereactor housing element 14 is affixed to theskin contacting element 24, which is adhered to the subject's skin, or directly to the skin (seeFIG. 1 ) the outward force in the direction normal to arrow 70 can result in small strains and stresses being applied to the patient's skin around thetissue site 20. These strains and stresses being applied to the patient's skin can be beneficial for the introduction of the cosmetic liquid or cream impregnated within thecosmetic pad 18 as well as providing a massaging effect of the skin. Where thereactor housing element 14 is made from a relatively more rigid material with respect to theskin contacting element 24, for example,flexible regions 74 can be provided in the lowerperipheral section 52 to facilitate outward movement of thereactor housing element 14 with respect to thetissue site 20 to allow for the small strains and stresses to be applied to the subject's skin at thetissue site 20. - The
reactor 16 is positioned in theenclosed volume 22 and is configured to react with the selected gas (e.g., nitrogen, oxygen, carbon dioxide) found in air. As thereactor 16 consumes the selected gas within theenclosed volume 22, the gas pressure within theenclosed volume 22 is reduced. For example, where thereactor 16 consumes oxygen, there can be an approximate 20% reduction from atmospheric pressure in theenclosed volume 22. An example of areactor 16 that can be used in the controlled pressure device is described in US 2014/0109890 A1, which is incorporated by reference herein. US 2014/0109890 A1 describes an oxygen based heater; however, the oxygen based heater described in US 2014/0109890 A1 can be used as thereactor 16 to consume oxygen within theenclosed volume 22 thus producing a partial vacuum within theenclosed volume 22. In this example, thereactor 16 includes a reducing agent, a binding agent on areactor substrate 80 and an electrolyte solution, which can be provided in an electrolyte impregnatedpad 82. The reducing agent on thereactor substrate 80 can be zinc, aluminum, or iron, for example. - As mentioned above, the
release layer 40 can operate as an air-tight barrier such that the selected gas (e.g., nitrogen, oxygen, carbon dioxide) is precluded from access to thereactor 16 until after the air-tight barrier, which in this instance is therelease layer 40, is removed from the controlledpressure device 10. Alternatively, the controlledpressure device 10 can include a package, which is shown inFIG. 2 as including anupper layer 94 and alower layer 96. Theupper layer 94 affixes to thelower layer 96 enclosing thereactor substrate 80 in between theupper layer 94 and thelower layer 96 so as to provide an air-tight seal so that the selected gas is precluded from access to thereactor 16. In this example including the package, theupper layer 94 or thelower layer 96 can operate as an air tight barrier in that removal of theupper layer 94 from thelower layer 96, or vice versa, allows the selected gas access to thereactor 16 so that the selected gas can be consumed by thereactor 16. Alternatively, at least one of the layers (thelower layer 96 in the illustrated embodiment) can includeopenings 98 and aseal layer 102 can be affixed in an air-tight manner to thelower layer 96 covering theopenings 98. Removal of theseal layer 102 from thelower layer 96 exposes thereactor 16 to the selected gas, which allows the reactor to consume the selected gas within theenclosed volume 22. The surface area of theopenings 98 can be appropriately sized to control the flow of the selected gas through the openings to sustain the chemical reaction of thereactor 16 to the desirable time limit for maintaining topical negative pressure on thetissue site 20 for the desired duration. Moreover,multiple seal layers 102 can be provided so that removal of one or a selected few of the seal layers (while other seal layers are still affixed to the lower layer 96) can also be provided to limit the flow of the selected gas toward thereactor 16. Additionally, to further control the pressure within the enclosed volume, the controlledpressure device 10 can include apressure relief valve 106 on thereactor housing element 14. Thepressure relief valve 106 can allow for selected communication between theenclosed volume 22 and ambient. Thepressure relief valve 106 can be operated when a predetermined pressure differential exists between theenclosed volume 22 and ambient. Moreover, thepressure relief valve 106 can be configured to open when the temperature within the enclosed volume exceeds a desired predetermined temperature. - To also further control the pressure within the
enclosed volume 22, the controlledpressure device 10 can be configured to allow an operator to change the size of theenclosed volume 22 while thereactor 16 consumes the selected gas in the enclosed volume, thus varying the gas pressure within theenclosed volume 22. For example, atab 110 can be affixed to thereactor housing element 14, and the operator can pull thetab 110 to move the reactor housing element away from thetissue site 20. InFIG. 2 , thetab 110 is affixed to thehood 50. When theenclosed volume 22 is under negative pressure, thehood 50 will tend to travel toward thetissue site 20. By pulling on thetab 110, thehood 50 can be moved away from thetissue site 20 and air can enter theenclosed volume 22, for example by leaking past thegasket 36 or a small pre-configured leakage path can be provided. Air entering theenclosed volume 22 can increase the pressure within theenclosed volume 22 until the selected gas (e.g., oxygen) is consumed by thereactor 16. Such a configuration can allow for a cycling of pressure in theenclosed volume 22. - The controlled
pressure device 10 can also be packaged such that thereactor housing element 14 and thereactor 16 are packaged separately from theskin contacting element 24, for example. In such an embodiment, a reactor housingelement release layer 120 can be provided. Thereactor housing element 14release layer 120 can be similar to therelease layer 40 having anupper side 122 that is releasable from thelower surface 56 of thereactor housing element 14. The reactor housingelement release layer 120 further includes alower surface 124 that is opposite to theupper side 122. The reactor housingelement release layer 120 can also be affixed to thelower layer 96, so that removal of the reactor housingelement release layer 120 from thereactor housing element 14 results in removal of thelower layer 96 from theupper layer 94, thus exposing thereactor 16 to air. Alternatively, the reactor housingelement release layer 120 can be affixed to theseal layer 102 such that removal of the reactor housingelement release layer 120 from thereactor housing element 14 results in removal of theseal layer 102 from thelower layer 96, thus exposing thereactor 16 to air via theopenings 98 provided in thelower layer 96. - Where the controlled
pressure device 10 is packaged where thereactor housing element 14 and thereactor 16 are separate from theskin contacting element 24, an upper skin contacting element release layer (not shown) can be provided. The upper skin contacting element release layer can be similar to therelease layer 40. Alternatively, no upper skin contacting element release layer need be provided. - The controlled
pressure device 10 further includes a liquid impermeable-airpermeable membrane 150 interposed between thereactor 16 and the cosmetic liquid or cream, which is impregnated in thecosmetic pad 18 in the illustrated embodiment. The size (area) of the liquid impermeable-airpermeable membrane 150 can depend on the location of the liquid impermeable-airpermeable membrane 150 within the controlledpressure device 10. If the cosmetic liquid or cream were to come in contact with thereactor 16, the chemical reaction of thereactor 16 when coming in contact with the selected gas may be detrimentally impacted. As such, the liquid impermeable-airpermeable membrane 150 allows air flow within theenclosed volume 22 while precluding the cosmetic liquid or cream from coming into contact with thereactor 16. - The liquid impermeable-air
permeable membrane 150 can be located in different locations on the controlledpressure device 10. In one example depicted inFIG. 2 , the liquid impermeable-airpermeable membrane 150 can be located between thereactor substrate 80 and thelower layer 96 making up the air-tight package for thereactor 16. So, once the lower layer 96 (or the seal layer 102) is removed, air can gain access to thereactor 16, but the cosmetic liquid or cream would be precluded from traveling through the liquid impermeable-airpermeable membrane 150. In another example, the liquid impermeable-airpermeable membrane 150 can be located between the lower layer 96 (or the seal layer 102) making up the air-tight package for thereactor 16 and the cosmetic liquid or cream, which can be impregnated in thecosmetic pad 18. More generally, and as depicted inFIG. 1 , the liquid impermeable-airpermeable membrane 150 can be located between thereactor 16 and the cosmetic liquid or cream, which would be impregnated in thecosmetic pad 18. As depicted inFIG. 1 , the liquid impermeable-airpermeable membrane 150 can be connected with thereactor housing element 14 and preclude the cosmetic liquid or cream from passing through the liquid impermeable-airpermeable membrane 150 while allowing air to travel through the liquid impermeable-airpermeable membrane 150 so that the selected gas can be removed from the enclosedvolume 22. If desired, the liquid impermeable-airpermeable membrane 150 could surround thereactor 16 and preclude the cosmetic liquid or cream from passing through the liquid impermeable-airpermeable membrane 150 while allowing air to travel through the liquid impermeable-airpermeable membrane 150. - In an embodiment where the
reactor housing element 14 and thereactor 16 are packaged separately from theskin contacting element 24, therelease layer 40 can be removed from theskin contacting element 24. Theskin contacting element 24 can be pressed against a subject's skin around thetissue site 20 and adhesive 38 on the skin contacting side of theskin contacting element 24 can adhere theskin contacting element 24 to the subject's skin. Theskin contacting gasket 36 can surround thetissue site 20 to promote an air-tight seal between theskin contacting element 24 and the subject's skin around thetissue site 20. The cosmetic liquid or cream, which is located within thecosmetic pad 18 in the illustrated embodiment, is then brought into contact with thetissue site 20 by traveling through theopenings 34. - The reactor housing
element release layer 120 can be removed from thereactor housing element 14. Removal of the reactor housingelement release layer 120 from thereactor housing element 14 can expose thereactor 16 to air by removal of thelower layer 96, theseal layer 102, or the reactor housingelement release layer 120 may be affixed in an air-tight manner to thereactor housing element 14 so that air is precluded from access to thereactor 16 until after the reactor housingelement release layer 120 is removed from thereactor housing element 14. After removal of the reactor housingelement release layer 120 from thereactor housing element 14, thelower surface 56 of thereactor housing element 14 can be brought in contact with anupper surface 152 of the liquid impermeable-airpermeable membrane 150, which can have itslower surface 154 affixed to theinterface side 32 of theskin contacting element 24. Alternatively, where the liquid impermeable-airpermeable membrane 150 is positioned between thereactor substrate 80 and thelower layer 96, thelower surface 56 of thereactor housing element 14 can be brought in contact with theinterface side 32 of theskin contacting element 24. When thereactor housing element 14 is brought into contact with the liquid impermeable-airpermeable membrane 150 and/or theskin contacting element 24, thereactor 16 consumes the selected gas found within theenclosed volume 22. A chemical reaction occurs where heat can be generated, and a pressure reduction with respect to atmospheric pressure occurs by consumption of the selected gas. Thereactor 16 can heat theenclosed volume 22 above ambient, which can provide a therapeutic effect for use with some cosmetic liquids or creams. In addition, suction can be applied to the tissue site thus stretching the subject's skin at the tissue site, which can also have a therapeutic effect with certain cosmetic liquids or creams. Moreover, the application of topical negative pressure at a particular tissue site can also have a therapeutic effect. - The controlled
pressure device 10 can be designed with certain parameters. As an example, assuming thetissue site 20 of about 10 cm×20 cm and an offset of the hood 50 (or the top of the reactor housing element 14) of about 2.5 cm from thetissue site 20 results in theenclosed volume 22 of 500 mL. Assuming that the cosmetic liquid or cream and the solid components of thecosmetic pad 18 in addition to thereactor 16 and any other solid components (e.g., the liquid impermeable-air permeable membrane 150) within theenclosed volume 22 account for 100 mL within theenclosed volume 22, this leaves 400 mL air in the enclosed volume. 400 mL of air results in about 320 mL of nitrogen and 80 mL of oxygen within theenclosed volume 22 prior to the application of a partial vacuum resulting from thereactor 16 consuming a selected gas in the air within theenclosed volume 22. One gram (1 g) of zinc (Zn) will consume about 170 mL at standard temperature and pressure (STP) of oxygen (02), which is the amount of oxygen in about 850 mL (STP) of normal dry air. Although theskin contacting gasket 36 and the reactorhousing element gasket 60 can be provided, there will likely be leakage of ambient air into theenclosed volume 22 past thegaskets reactor housing element 14 and theskin contacting element 24. For the purposes of this disclosure, both leakage past interfaces (e.g., leakage around the skin contacting gasket 36) and diffusion (e.g., diffusion through the reactor housing element 14) will be referred to as leakage. Thegaskets skin contacting element 24 andreactor housing element 14 are configured to have a maximum leakage rate of air into theenclosed volume 22 from ambient. For example, a maximum leakage rate of 1 mL (STP)/hour of air into the enclosed volume from ambient results in 0.2 mL (STP) of oxygen/hour. Since 1 g of zinc consumes 170 mL of oxygen (STP), 1 g of zinc provides an adequate amount of a reducing agent to result in a 20% reduction from normal atmospheric pressure within theenclosed volume 22 for an extended period of time, e.g., well over 72 hours. The controlledpressure device 10 will likely be worn for a much shorter period of time and thetissue site 20 being treated may be much smaller than 10 cm×20 cm. It can be seen that a verysmall reactor 16, e.g., one able to accommodate less than 1 g of zinc, can be used in the controlledpressure device 10. - In view of the foregoing, the controlled
pressure device 10 can be configured as follows. Thereactor 16 can be configured to have a predetermined scavenging capacity (“SC”), which relates to the volume of the selected gas that thereactor 16 is configured to consume. For example, as mentioned above 1 g of zinc will consume about 170 mL of oxygen (STP), so the scavenging capacity would be 170 mL. Theenclosed volume 22 can have a determined volume (“DV”) based on the area of thetissue site 20, the size of thereactor housing element 14, the offset of the hood 50 (or top of the reactor housing element 14) from thetissue site 20, taking into account the cosmetic liquid or cream and the solid components of thecosmetic pad 18 in addition to thereactor 16 and any other solid components within theenclosed volume 22. For example, the determined volume of 400 mL was discussed above. Also, the controlledpressure device 10 can be configured to have a maximum leakage rate (LR) for air entering theenclosed volume 22. In addition, the controlledpressure device 10 can be configured to have a minimum wear time (“MWT”), which relates to the minimum amount of time that the controlledpressure device 10 is configured to be worn. Assuming that it is desirable to have thereactor 16 consume, or scavenge, the selected gas for the entire minimum wear time, the controlled pressure device can be configured in view of the following relationship: -
SC>DV*(% of selected gas in air)+LR*(% of selected gas in air)*MWT. - The scavenging capacity can be determined to provide a relatively
small reactor 16 in relation to thereactor housing element 14 and thetissue site 20 to be treated. The determined volume can be determined to provide a relativelysmall reactor 16 andreactor housing element 14 in view thetissue site 20 to be treated. The maximum leakage rate for air entering theenclosed volume 22 should be reduced as much as is practical; however, there may be some circumstances in which a predetermined amount of leakage is desirable, for example where cycling of pressure within theenclosed volume 22 is desired. For example, the maximum leakage rate for air entering theenclosed volume 22 can be less than 10 mL/hour, and preferably less than 1 or 2 mL/hr. The minimum wear time can be determined based on the desired amount of time the topical negative pressure is to be applied to thetissue site 20. It may be desirable to include a safety factor (e.g., a multiplier on the right side of the relationship above) to accommodate for manufacturing tolerances, differences among tissues sites and subjects placing the controlledpressure device 10 on thetissue site 20. - As the
reactor 16 consumes the selected gas found in air within theenclosed volume 22, an exothermic reaction occurs such that there is an increase in temperature of thereactor 16. As such, thereactor 16 can operate as a heater to heat the cosmetic liquid or cream impregnated in thecosmetic pad 18. This can change the viscosity of the cosmetic liquid or cream, which can facilitate entry of the cosmetic liquid or cream into skin pores. - The
reactor housing element 14 could also be provided with aremovable section 160 that when removed could provide ambient air access to thereactor 16 or an additional reactor located beneath thereactor housing element 14. For example, theremovable section 160 can be affixed to theupper layer 94 of the package in which thereactor substrate 80 is located. Removal of theremovable section 160 can result in removal of at least a portion of theupper layer 94 thus exposing thereactor substrate 80 to ambient air, which would result in an exothermic reaction. Alternatively, an additional reactor could be located beneath thereactor housing element 14 and removal of theremovable section 160 can result in removal of at least a portion of the package (similar to the package made up of theupper layer 94 and the lower layer 96) thus exposing the additional reactor to ambient air. The additional reactor can also heat the gas in theenclosed volume 22, which can heat thetissue site 20. - Different types of reactors could be used to provide topical negative pressure inside the
enclosed volume 22 of the controlledpressure device 10.FIG. 3 depicts multiple reactor substrates or multiple regions on the same reactor substrate, which are depicted asreactor elements first reactor element 80 a can be configured to begin consuming oxygen after being exposed to oxygen for a very short (first) period of time t1, e.g., nearly instantaneously. Thesecond reactor element 80 b can be configured to begin consuming oxygen after being exposed to oxygen for a longer (second) period of time t2, and thethird reactor element 80 c can be configured to begin consuming oxygen after being exposed to oxygen for an even longer (third) period of time. Alternatively, thesecond reactor element 80 b can be configured with a delayed reaction time to begin consuming oxygen after thefirst reactor element 80 a has been exhausted and no longer consumes oxygen. Similarly, thethird reactor element 80 c can be configured with a delayed reaction time to begin consuming oxygen after thefirst reactor element 80 a and thesecond reactor element 80 b have both been exhausted and no longer consume oxygen. Such a configuration can allow for a cycling of pressure in theenclosed volume 22. - In lieu of the
reactor 16 made up of thereactor substrate 80, thereactor 16 may be one or any combination of a zinc-based chemical pump, electro-chemical pumps, vacuum-on-demand devices (referred to herein as VOD), electrolyzers, pressure-reducing solid state devices, oxygen absorbing iron packets, or getters of zirconium titanium, vanadium iron, lithium, lithium metal, magnesium, calcium, lithium barium combinations, zinc-air battery, zinc-air battery components or other materials highly reactive with the selected gases, for example, nitrogen, carbon dioxide and oxygen gases found in skin tissue environments. -
FIG. 4 depicts anotherreactor 226 that can be used in place of thereactor 16 shown inFIG. 1 . WO 2015/054040 A1, which is incorporated by reference, describes an electrochemical cell that is adapted to consume gases, i.e., air or its gaseous non-noble constituents, within an enclosure via an electrochemical reaction. This consumption of gas within a sealed enclosure forms a partial vacuum. The controlledpressure device 10 can include such areactor 226 having anelectrochemical cell 228 that lowers the pressure within theenclosed volume 22 through an electrochemical reaction that takes place when a voltage is applied to theelectrochemical cell 228 by a power source 230 (depicted schematically inFIG. 4 ). Operation ofelectrochemical cell 228 in this example can also be achieved by controlling the current supplied to theelectrochemical cell 228 by thepower source 230, for example by providing aswitch 232 that can be operated by the user. Thepower source 230 can be located in theenclosed volume 22 or be provided outside the controlled pressure device 10 (e.g. on the reactor housing element 14). Theswitch 232 can be provided outside the controlled pressure device 10 (e.g. on the reactor housing element 14). - In an example where the reactor is a VOD device, a VOD is a solid state electrochemical cell, which when charged with a low voltage, produces a highly reactive material that captures gases present in the atmosphere and when sealed in an air tight system can form a partial vacuum. In a VOD device, metal is deposited to grow dendrites as a voltage is applied across electrodes of the VOD device and lithium salt electrolyte, charging the VOD device. Similar to charging a battery, electrons are moved from layer to layer to form metallic lithium.
- In an example where the reactor is a getter, a getter, as known in the art, is a deposit of reactor material that is used for initiating and maintaining a partial vacuum. When gas molecules strike the getter material, particular gas molecules (i.e., those of the selected gas) combine with the getter chemically or by adsorption. Thus the getter removes the selected gas from the evacuated space until the active material is exhausted.
- A reactor having a self-regulating oxygen getter powered by zinc-air battery technology may be used in lieu of the above-described
reactor 16 made up of thereactor substrate 80. Zinc-air batteries can react to control or reduce the oxygen levels in sealed site and thus self-regulate a reduced pressure of approximately 0.8 bars. If the zinc-air battery components are configured as a working zinc-air battery, the battery voltage will drop when the oxygen has been depleted and the desired partial vacuum pressure will have been achieved. This drop in voltage may be used to indicate that the desired partial vacuum has been achieved. For example, a 675 size hearing aid zinc-air battery is rated at 620 mAh, occupies 0.5 mL volume, and weighs 1.9 g. A 675 zinc-air battery can remove more than 150 times its volume of oxygen. - The
cosmetic pad 18 can be made from a blend of polyester and cellulose fibers, polypropylene fibers, or other suitable non-woven polymeric material. The cosmetic liquid or cream can include at least one of a moisturizer, dimethylaminoethanol (DMAE), Acetyl hexapeptide-8, Acetyl hexapeptide-3, retinol, ubiquinone, dithiolane-3-pentanic acid, alpha-hydroxy acid, alpha lipoic acid, salicylic acid, hydrocortisone, topical botulinum cream, and hyaluronic acid. Thecosmetic pad 18 can includetop surface 180 and abottom surface 182, which is opposite thetop surface 180. Thebottom surface 182 can be undulated havinghills 184 andvalleys 186, which can allow thecosmetic pad 18 to act as a skin massaging element. Anadditional membrane 188 could be provided and located beneath thecosmetic pad 18 to act as the skin massaging element. Thisadditional membrane 188 would also be positioned adjacent to thetissue site 20. Thisadditional membrane 188 could also include an undulated bottom surface, similar to thebottom surface 182 havinghills 184 andvalleys 186. Thisadditional membrane 188 would also include openings to allow the cosmetic liquid or cream to pass through the openings to thetissue site 20. When a partial vacuum is provided in theenclosed volume 22, the skin can be drawn towards the undulated surface and the skin can conform to thehills 184 andvalleys 186. Accordingly, small strains and stresses can applied to the patient's skin at thetissue site 20 providing a massaging effect. - The controlled
pressure device 10 can also include additional powered components, which is shown as apowered component 240 that is schematically depicted inFIG. 2 . Eachpowered component 240, which are described later with reference toFIGS. 5-7 , can be electrically connected with a power source 242 (depicted schematically inFIG. 2 ) which, for example, can be a zinc-air battery exposed to ambient or a zinc MnO2 battery, electrically connected with thepowered component 240. When using a zinc-air battery as thepower source 242, thepower source 242 would be located outside of theenclosed volume 22 or a section of thereactor housing element 14 or theskin contacting element 24 could be removable to allow ambient air to contact the zinc-air battery. -
FIG. 5 depicts aheater 250, which is one example of apowered component 240 that can be used in the controlledpressure device 10, electrically connected with thepower source 242. Theheater 250 can be a thin film heater or thin film nano wire heater. Theheater 250 can heat the cosmetic liquid or cream impregnated in thecosmetic pad 18. Theheater 250 can be positioned adjacent to thecosmetic pad 18. Aswitch 252 can be provided to control power to theheater 250. Theheater 250 can also heat the gas in theenclosed volume 22, which can heat thetissue site 20. -
FIG. 6 depicts afirst electrode 260 and asecond electrode 262 electrically connected with thepower source 242. The electrodes are another example of apowered component 240 that can be used in the controlledpressure device 10. Theswitch 252 can be provided to control power to theelectrodes first electrode 260 can be positioned on a first side of thetissue site 20 and in contact with the skin, and thesecond electrode 262 can be positioned on a second, opposite, side of thetissue site 20 and in contact with the skin. Theelectrodes tissue site 20. -
FIG. 7 depicts alight source 280, which is another example of apowered component 240 that can be used in the controlledpressure device 10. Thelight source 280 can include a plurality ofLEDs 282 mounted on aflexible substrate 284. TheLEDs 282 are electrically connected with thepower source 242. Theflexible substrate 284 can be placed adjacent to theskin contacting element 24, which can includelarger openings 34, which can allow light to pass for phototherapy. -
FIG. 8 depicts a method of treating tissue using negative pressure. Although theFIG. 8 shows a specific order of method steps, the order of the steps may differ from what is depicted. Also two or more steps may be performed concurrently or with partial concurrence. The method will be described with reference to the controlledpressure device 10 depicted inFIGS. 1 and 2 , however, the method can be practiced with other devices. - At 300, the reactor housing
element release layer 120 is removed from thereactor housing element 14. Removal of the reactor housingelement release layer 120 from thereactor housing element 14 can allow air to contact thereactor 16, which can begin the reaction in which oxygen (or another selected gas in air) is being consumed by thereactor 16. At 302, thereactor housing element 14, thereactor 16 and the liquid impermeable—airpermeable membrane 150 are placed over thetissue site 20. At 304, thereactor housing element 14 is affixed with respect to the skin around thetissue site 20 to define an at least substantially air-tightenclosed volume 22 around the tissue site. Thereactor 16 can consume the selected gas (e.g., oxygen) from the enclosedvolume 22 thus reducing the gas pressure in theenclosed volume 22. -
FIG. 9 depicts other steps in a method of treating tissue using negative pressure. For example, the method may include, at 310, placing a cosmetic liquid or cream on thetissue site 20. The cosmetic liquid or cream may be placed on thetissue site 20 prior to placing thereactor housing element 14, thereactor 16 and the liquid impermeable—airpermeable membrane 150 over thetissue site 20, which occurs atstep 302. - The method of treating tissue using negative pressure may also include, at 312, placing a
pad 18 impregnated or wetted with a cosmetic liquid or cream over thetissue site 20. Thepad 18 can be connected with thereactor housing element 14 in such a manner that thepad 18 is placed on thetissue site 20 while placing thereactor housing element 14, thereactor 16 and the liquid impermeable—airpermeable membrane 150 over thetissue site 20. - The method of treating tissue using negative pressure may also include, at 314, removing the
release layer 40 from theskin contacting element 24, and, at 316, placing theskin contacting element 24 over or around thetissue site 20. Theskin contacting element 24 can be placed over or around thetissue site 20 prior to placing thereactor housing element 14, thereactor 16 and the liquid impermeable—airpermeable membrane 150 over thetissue site 20, which occurs atstep 302. As such, affixing thereactor housing element 14 with respect to skin around the tissue site, which occurs atstep 304, can further include affixing thereactor housing element 14 to theskin contacting element 24, at 318. The method may also include affixing theskin contacting element 24 to the skin around thetissue site 20, at 320. - It will be appreciated that various of the above-disclosed controlled pressure device and other features and functions, or alternatives or varieties thereof, may be desirably combined into many other different systems or applications. Also that various presently unforeseen or unanticipated alternatives, modifications, variations or improvements therein may be subsequently made by those skilled in the art which are also intended to be encompassed by the following claims.
Claims (33)
SC>DV*(% of selected gas in air)+LR*(% of selected gas in air)*MWT.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/771,841 US20180318165A1 (en) | 2015-10-30 | 2016-10-28 | Tissue treatment device and method |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562248422P | 2015-10-30 | 2015-10-30 | |
US15/771,841 US20180318165A1 (en) | 2015-10-30 | 2016-10-28 | Tissue treatment device and method |
PCT/US2016/059291 WO2017075331A1 (en) | 2015-10-30 | 2016-10-28 | Tissue treatment device and method |
Publications (1)
Publication Number | Publication Date |
---|---|
US20180318165A1 true US20180318165A1 (en) | 2018-11-08 |
Family
ID=58631121
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/771,841 Abandoned US20180318165A1 (en) | 2015-10-30 | 2016-10-28 | Tissue treatment device and method |
US15/771,843 Active US10449094B2 (en) | 2015-10-30 | 2016-10-28 | Wound therapy device and method |
US16/561,121 Active US11071652B2 (en) | 2015-10-30 | 2019-09-05 | Wound therapy device and method |
US17/351,749 Active 2037-04-01 US11759368B2 (en) | 2015-10-30 | 2021-06-18 | Wound therapy device and method |
US18/231,349 Pending US20230381027A1 (en) | 2015-10-30 | 2023-08-08 | Wound therapy device and method |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/771,843 Active US10449094B2 (en) | 2015-10-30 | 2016-10-28 | Wound therapy device and method |
US16/561,121 Active US11071652B2 (en) | 2015-10-30 | 2019-09-05 | Wound therapy device and method |
US17/351,749 Active 2037-04-01 US11759368B2 (en) | 2015-10-30 | 2021-06-18 | Wound therapy device and method |
US18/231,349 Pending US20230381027A1 (en) | 2015-10-30 | 2023-08-08 | Wound therapy device and method |
Country Status (10)
Country | Link |
---|---|
US (5) | US20180318165A1 (en) |
EP (2) | EP3367986B1 (en) |
JP (2) | JP6703125B2 (en) |
KR (2) | KR20180078258A (en) |
CN (2) | CN108472157B (en) |
AU (3) | AU2016344202B2 (en) |
CA (2) | CA3003134A1 (en) |
DK (1) | DK3367987T3 (en) |
RU (1) | RU2729930C2 (en) |
WO (2) | WO2017075381A1 (en) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190029917A1 (en) * | 2017-07-28 | 2019-01-31 | L'oreal | Multi-action lip-enhancement device |
US20190231670A1 (en) * | 2016-10-28 | 2019-08-01 | Coty Inc. | Topical composition |
US10449094B2 (en) * | 2015-10-30 | 2019-10-22 | Lorain County Community College Innovation Foundation | Wound therapy device and method |
WO2020176373A1 (en) * | 2019-02-28 | 2020-09-03 | Aatru Medical, LLC | Chemical pump housing for negative pressure system |
USD898925S1 (en) | 2018-09-13 | 2020-10-13 | Smith & Nephew Plc | Medical dressing |
US10881553B1 (en) * | 2019-10-03 | 2021-01-05 | Advanced Dressing, LLC | Reduced pressure device having selectively deliverable electrolyte |
US10898388B2 (en) | 2015-04-27 | 2021-01-26 | Smith & Nephew Plc | Reduced pressure apparatuses and methods |
WO2021021851A1 (en) * | 2019-07-30 | 2021-02-04 | Advanced Dressing, LLC | Dressing for providing low oxygen environment |
US11096831B2 (en) | 2016-05-03 | 2021-08-24 | Smith & Nephew Plc | Negative pressure wound therapy device activation and control |
US20210267638A1 (en) * | 2018-07-05 | 2021-09-02 | W.O.M. World Of Medicine Gmbh | Insufflation device with intelligent control of smoke evacuation |
US11116669B2 (en) | 2016-08-25 | 2021-09-14 | Smith & Nephew Plc | Absorbent negative pressure wound therapy dressing |
US11123471B2 (en) | 2017-03-08 | 2021-09-21 | Smith & Nephew Plc | Negative pressure wound therapy device control in presence of fault condition |
US11160915B2 (en) | 2017-05-09 | 2021-11-02 | Smith & Nephew Plc | Redundant controls for negative pressure wound therapy systems |
US11173240B2 (en) | 2016-05-03 | 2021-11-16 | Smith & Nephew Plc | Optimizing power transfer to negative pressure sources in negative pressure therapy systems |
US11285047B2 (en) | 2016-04-26 | 2022-03-29 | Smith & Nephew Plc | Wound dressings and methods of use with integrated negative pressure source having a fluid ingress inhibition component |
US11305047B2 (en) | 2016-05-03 | 2022-04-19 | Smith & Nephew Plc | Systems and methods for driving negative pressure sources in negative pressure therapy systems |
US11497653B2 (en) | 2017-11-01 | 2022-11-15 | Smith & Nephew Plc | Negative pressure wound treatment apparatuses and methods with integrated electronics |
US11554203B2 (en) | 2017-11-01 | 2023-01-17 | Smith & Nephew Plc | Negative pressure wound treatment apparatuses and methods with integrated electronics |
US11564847B2 (en) | 2016-09-30 | 2023-01-31 | Smith & Nephew Plc | Negative pressure wound treatment apparatuses and methods with integrated electronics |
US11564845B2 (en) | 2017-09-13 | 2023-01-31 | Smith & Nephew Plc | Negative pressure wound treatment apparatuses and methods with integrated electronics |
US11701265B2 (en) | 2017-09-13 | 2023-07-18 | Smith & Nephew Plc | Negative pressure wound treatment apparatuses and methods with integrated electronics |
US11707564B2 (en) | 2017-11-01 | 2023-07-25 | Smith & Nephew Plc | Safe operation of integrated negative pressure wound treatment apparatuses |
US11723809B2 (en) | 2016-03-07 | 2023-08-15 | Smith & Nephew Plc | Wound treatment apparatuses and methods with negative pressure source integrated into wound dressing |
EP4041165A4 (en) * | 2019-10-03 | 2023-10-25 | Aatru Medical, LLC | Negative pressure treatment including mechanical and chemical pump |
US12005182B2 (en) | 2019-05-31 | 2024-06-11 | T.J.Smith And Nephew, Limited | Systems and methods for extending operational time of negative pressure wound treatment apparatuses |
US12005181B2 (en) | 2016-12-12 | 2024-06-11 | Smith & Nephew Plc | Pressure wound therapy status indication via external device |
US12083263B2 (en) | 2019-03-20 | 2024-09-10 | Smith & Nephew Plc | Negative pressure wound treatment apparatuses and methods with integrated electronics |
US12097097B2 (en) | 2023-05-26 | 2024-09-24 | Smith & Nephew Plc | Negative pressure wound treatment apparatuses and methods with integrated electronics |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0808376D0 (en) | 2008-05-08 | 2008-06-18 | Bristol Myers Squibb Co | Wound dressing |
GB0817796D0 (en) | 2008-09-29 | 2008-11-05 | Convatec Inc | wound dressing |
GB201020236D0 (en) | 2010-11-30 | 2011-01-12 | Convatec Technologies Inc | A composition for detecting biofilms on viable tissues |
JP6151186B2 (en) | 2010-12-08 | 2017-06-21 | コンバテック・テクノロジーズ・インコーポレイテッドConvatec Technologies Inc | Wound exudate system attachment device |
JP5965409B2 (en) | 2010-12-08 | 2016-08-03 | コンバテック・テクノロジーズ・インコーポレイテッドConvatec Technologies Inc | Integrated system for assessing wound exudate |
GB201115182D0 (en) | 2011-09-02 | 2011-10-19 | Trio Healthcare Ltd | Skin contact material |
GB2497406A (en) | 2011-11-29 | 2013-06-12 | Webtec Converting Llc | Dressing with a perforated binder layer |
CA2895896A1 (en) | 2012-12-20 | 2014-06-26 | Convatec Technologies Inc. | Processing of chemically modified cellulosic fibres |
EP3435941B1 (en) | 2016-03-30 | 2021-09-01 | ConvaTec Technologies Inc. | Detecting microbial infections in wounds |
BR112018070238A2 (en) | 2016-03-30 | 2019-01-29 | Acib Gmbh | detection of microbial wound infection |
KR20190026858A (en) | 2016-07-08 | 2019-03-13 | 컨바텍 테크놀러지스 인크 | Flexible negative pressure system |
ES2912094T3 (en) | 2016-07-08 | 2022-05-24 | Convatec Technologies Inc | Fluid flow detection |
KR20190028467A (en) | 2016-07-08 | 2019-03-18 | 컨바텍 테크놀러지스 인크 | Body fluid collecting device |
US11504268B2 (en) * | 2018-06-27 | 2022-11-22 | Ethicon, Inc. | Wound treatment system |
CN108992327A (en) * | 2018-07-30 | 2018-12-14 | 吴威 | A kind of liquid layered wrinkle-removal cosmetic instrument |
KR102158607B1 (en) * | 2018-08-24 | 2020-09-22 | 한국과학기술원 | Smart dressing with liquid guiding pad for monitorng wound infection |
US20210299347A1 (en) * | 2018-08-28 | 2021-09-30 | Aatru Medical, LLC | Negative pressure device having oxygen scavenger and volume reduction |
CN112601573A (en) * | 2018-08-29 | 2021-04-02 | 埃埃特鲁医疗有限责任公司 | Negative pressure therapy including mechanical pump and chemical pump |
WO2020106383A1 (en) * | 2018-11-20 | 2020-05-28 | Aatru Medical, LLC | Negative pressure device including expandable segment |
US20220008642A1 (en) * | 2018-11-20 | 2022-01-13 | Kci Licensing, Inc. | System And Apparatus For Wound Exudate Assessment |
EP3917472A1 (en) * | 2019-01-29 | 2021-12-08 | KCI Licensing, Inc. | Absorbent dressing with indicator and mechanical decoupling of expansion forces |
CN110025462B (en) * | 2019-05-15 | 2023-12-12 | 宁波市瑞尔芭比医疗设备有限公司 | Scraping instrument |
JP7511585B2 (en) | 2019-06-03 | 2024-07-05 | コンバテック リミティド | Methods and devices for destroying and containing pathogens - Patents.com |
EP3999007A4 (en) * | 2019-07-17 | 2023-08-02 | Aatru Medical, LLC | Negative pressure device for articulating joint |
US11331221B2 (en) | 2019-12-27 | 2022-05-17 | Convatec Limited | Negative pressure wound dressing |
US11771819B2 (en) | 2019-12-27 | 2023-10-03 | Convatec Limited | Low profile filter devices suitable for use in negative pressure wound therapy systems |
CN111420291B (en) * | 2020-03-31 | 2022-01-25 | 河南科技大学第一附属医院 | Box type infrared anti-escape baking lamp |
WO2021257508A1 (en) * | 2020-06-16 | 2021-12-23 | Advanced Dressing, LLC | Controlled oxygen dressing |
US20230218444A1 (en) * | 2020-06-16 | 2023-07-13 | Aatru Medical, LLC | Negative pressure wound therapy device with oxygen control |
US20220117783A1 (en) * | 2020-10-16 | 2022-04-21 | Mark Lobanoff | Silicone device for corneal cross-linking |
KR20220107101A (en) | 2021-01-24 | 2022-08-02 | 최형준 | Method for plastics' high stiffness and impact resistance |
KR20210019470A (en) | 2021-02-02 | 2021-02-22 | 최형준 | Mass production technology for high stiffiness and impact resistance fiber reinforcement plastic |
US11911605B2 (en) | 2021-03-05 | 2024-02-27 | Truerelief Llc | Method and apparatus for injury treatment |
WO2023107344A1 (en) * | 2021-12-06 | 2023-06-15 | Aatru Medical, LLC | Negative pressure dressing assembly |
WO2024026308A2 (en) | 2022-07-29 | 2024-02-01 | Massachusetts Institute Of Technology | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE SIGNAL REGULATORY PROTEIN ALPHA (SIRPα) GENE |
CN117504122B (en) * | 2023-11-08 | 2024-07-02 | 深圳市兆兴博拓科技股份有限公司 | Pulse physiotherapy instrument, electrode assembly thereof and pulse physiotherapy control method |
Citations (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2477403A (en) * | 1944-11-24 | 1949-07-26 | Owens Corning Fiberglass Corp | Surgical bandage |
US4667665A (en) * | 1984-08-16 | 1987-05-26 | Colin O'D. Offenhartz | Non-occlusive burn and trauma dressing |
US5052381A (en) * | 1990-03-19 | 1991-10-01 | The B. F. Goodrich Company | Adhesive wound dressing and perforated shield |
US5409472A (en) * | 1989-08-03 | 1995-04-25 | Smith & Nephew Plc | Adhesive polymeric foam dressings |
US5578022A (en) * | 1995-04-12 | 1996-11-26 | Scherson; Daniel A. | Oxygen producing bandage and method |
US5607388A (en) * | 1994-06-16 | 1997-03-04 | Hercules Incorporated | Multi-purpose wound dressing |
US5639568A (en) * | 1995-10-16 | 1997-06-17 | Aer Energy Resources, Inc. | Split anode for a dual air electrode cell |
US5910125A (en) * | 1991-10-23 | 1999-06-08 | Cummings; Gary Wayne | Composite wound dressing with separable components |
US6171368B1 (en) * | 1998-11-06 | 2001-01-09 | Med-E-Cell | Gas extraction from closed containers |
US6336935B1 (en) * | 1999-09-15 | 2002-01-08 | The Procter & Gamble Company | Disposable thermal body wrap |
US6465709B1 (en) * | 1999-07-08 | 2002-10-15 | Johnson & Johnson Consumer Companies, Inc. | Exothermic bandage |
US20030162095A1 (en) * | 2002-02-22 | 2003-08-28 | John Huang | Battery with a controlled release anode |
US6756053B2 (en) * | 1995-07-28 | 2004-06-29 | Zars, Inc. | Controlled heat induced rapid delivery of pharmaceuticals from skin depot |
US6890553B1 (en) * | 1999-07-08 | 2005-05-10 | Johnson & Johnson Consumer Companies, Inc. | Exothermic topical delivery device |
US6893453B2 (en) * | 2002-12-17 | 2005-05-17 | Kimberly-Clark Worldwide, Inc. | Thermal therapy pad with variable heat control |
US7108440B1 (en) * | 1999-10-08 | 2006-09-19 | The Procter & Gamble Company | Applicator for distributing a substance onto a target surface |
US20070055209A1 (en) * | 2005-09-07 | 2007-03-08 | Patel Harish A | Self contained wound dressing apparatus |
WO2007070151A1 (en) * | 2005-12-15 | 2007-06-21 | Kimberly-Clark Worldwide, Inc. | Therapeutic kit employing a thermal insert |
US7238849B2 (en) * | 1999-03-17 | 2007-07-03 | Barbara Sheila Goldberg | Adhesive dispensing arrangement |
US7457667B2 (en) * | 2004-02-19 | 2008-11-25 | Silverleaf Medical Products, Inc. | Current producing surface for a wound dressing |
US20110045222A1 (en) * | 2009-08-19 | 2011-02-24 | Eastman Chemical Company | Oxygen-scavenging polymer blends suitable for use in packaging |
US8012169B2 (en) * | 2003-09-08 | 2011-09-06 | Microlin, Llc | Electrochemical wound therapy device |
US8439894B1 (en) * | 2011-03-07 | 2013-05-14 | Larry W. Miller | Negative pressure bandage with internal storage chamber |
US20140109890A1 (en) * | 2012-10-19 | 2014-04-24 | Rechargeable Battery Corporation | Electrolyte Formulations For Oxygen Activated Portable Heater |
US20150159066A1 (en) * | 2011-11-25 | 2015-06-11 | Smith & Nephew Plc | Composition, apparatus, kit and method and uses thereof |
US9882196B2 (en) * | 2014-07-02 | 2018-01-30 | Pellion Technologies, Inc. | Multi-electrode electrochemical cell and method of making the same |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3012169A (en) | 1959-04-22 | 1961-12-05 | Sylvania Electric Prod | Anode assembly mechanism |
CA984567A (en) * | 1972-02-16 | 1976-03-02 | Albert E. Smith | Microporous polymer sheets |
US6040493A (en) * | 1998-04-24 | 2000-03-21 | Replication Medical, Inc. | Bioreactor wound dressing |
EP1194092B1 (en) | 1999-07-08 | 2007-03-14 | Johnson & Johnson Consumer Companies, Inc. | Exothermic topical delivery device |
US6179804B1 (en) * | 1999-08-18 | 2001-01-30 | Oxypatch, Llc | Treatment apparatus for wounds |
US6669966B1 (en) * | 2000-01-06 | 2003-12-30 | Marantech Holding Llc | Compositions for facilitating skin growth and methods and articles using same |
US8915894B1 (en) * | 2000-01-24 | 2014-12-23 | Meditech Development Incorporated | Vacuum cup for delivery of agents during vacuum treatment |
US7700819B2 (en) * | 2001-02-16 | 2010-04-20 | Kci Licensing, Inc. | Biocompatible wound dressing |
US6767342B1 (en) * | 2001-04-23 | 2004-07-27 | Evelyna D. Cantwell | Oxygen bandage system |
US7922676B2 (en) | 2003-09-10 | 2011-04-12 | Power Paper, Ltd. | Disposable electric bandage |
GB0325129D0 (en) * | 2003-10-28 | 2003-12-03 | Smith & Nephew | Apparatus in situ |
US20060235358A1 (en) * | 2005-04-18 | 2006-10-19 | Jose Azocar | Method and apparatus for tissue oxygenation |
US8586818B2 (en) | 2005-12-15 | 2013-11-19 | Aalnex, Inc. | Wound shield |
US7615036B2 (en) | 2006-05-11 | 2009-11-10 | Kalypto Medical, Inc. | Device and method for wound therapy |
US7779625B2 (en) | 2006-05-11 | 2010-08-24 | Kalypto Medical, Inc. | Device and method for wound therapy |
US20080082069A1 (en) * | 2006-10-02 | 2008-04-03 | Jian Qin | Absorbent articles comprising carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks |
MX2010005553A (en) * | 2007-11-21 | 2010-06-01 | Smith & Nephew | Wound dressing. |
US20090202617A1 (en) * | 2008-02-13 | 2009-08-13 | Ward Kevin R | Gas based wound and tissue therapeutics |
US8449508B2 (en) * | 2008-03-05 | 2013-05-28 | Kci Licensing, Inc. | Dressing and method for applying reduced pressure to and collecting and storing fluid from a tissue site |
CN101959479B (en) | 2008-03-05 | 2014-08-20 | 凯希特许有限公司 | Dressing and method for applying reduced pressure to and collecting and storing fluid from a tissue site |
SE0801375L (en) | 2008-06-12 | 2009-12-13 | Moelnlycke Health Care Ab | Wound dressings |
US8439860B2 (en) * | 2009-02-24 | 2013-05-14 | Neogenix, Llc | Oxygen-producing bandage with releasable oxygen source |
GB201006988D0 (en) * | 2010-04-27 | 2010-06-09 | Smith & Nephew | Suction port |
WO2012064908A1 (en) * | 2010-11-12 | 2012-05-18 | The Procter & Gamble Company | Elastomeric compositions that resist force loss |
US8768426B2 (en) * | 2011-03-31 | 2014-07-01 | Covidien Lp | Y-shaped ear sensor with strain relief |
US8532729B2 (en) * | 2011-03-31 | 2013-09-10 | Covidien Lp | Moldable ear sensor |
US9687669B2 (en) | 2011-11-09 | 2017-06-27 | John Stephan | Wearable light therapy apparatus |
JP6162149B2 (en) * | 2012-01-18 | 2017-07-12 | ワールドワイド イノベーティブ ヘルスケア,インコーポレイテッド | Correctable skin closure dressing |
AU2013234034B2 (en) * | 2012-03-12 | 2017-03-30 | Smith & Nephew Plc | Reduced pressure apparatus and methods |
JP6238417B2 (en) | 2012-03-28 | 2017-11-29 | ケーシーアイ ライセンシング インコーポレイテッド | Vacuum system, dressing and method for facilitating separation of electronic and clinical components |
US10441588B2 (en) * | 2012-05-02 | 2019-10-15 | Curators Of The University Of Missouri | Methods and compositions for treating bacterial infection |
US9814719B2 (en) * | 2012-05-02 | 2017-11-14 | Curators Of The University Of Missouri | Methods and compositions for treating bacterial infection |
CN202568632U (en) * | 2012-05-04 | 2012-12-05 | 王宏坤 | Bag-shaped vacuum wound dressing |
US9345869B2 (en) * | 2012-10-11 | 2016-05-24 | Owl Manor Medical, Llc | Oxygen diffusive wound dressings and methods of manufacturing and use |
US9480830B1 (en) * | 2013-04-16 | 2016-11-01 | Jose Azocar | Assembly for tissue oxygenation and method of use |
CN105451550A (en) * | 2013-07-01 | 2016-03-30 | 3M创新有限公司 | Antimicrobial foams and methods of making same |
JP6063363B2 (en) | 2013-09-11 | 2017-01-18 | 株式会社日立製作所 | Magnetic resonance imaging apparatus, imaging parameter determination method, and imaging parameter determination program |
WO2015054040A1 (en) * | 2013-10-07 | 2015-04-16 | Scherson Daniel | Electrochemical method and apparatus for forming a vacuum in a sealed enclosure |
MX2017013680A (en) * | 2015-04-29 | 2018-05-22 | Bsn Medical Gmbh | Medical bathing device. |
AU2016344202B2 (en) * | 2015-10-30 | 2020-10-29 | Advanced Dressings, LLC | Tissue treatment device and method |
US10046095B1 (en) * | 2017-04-04 | 2018-08-14 | Aatru Medical, LLC | Wound therapy device and method |
-
2016
- 2016-10-28 AU AU2016344202A patent/AU2016344202B2/en active Active
- 2016-10-28 KR KR1020187013449A patent/KR20180078258A/en not_active Application Discontinuation
- 2016-10-28 WO PCT/US2016/059364 patent/WO2017075381A1/en active Application Filing
- 2016-10-28 AU AU2016343674A patent/AU2016343674C1/en active Active
- 2016-10-28 EP EP16860863.6A patent/EP3367986B1/en active Active
- 2016-10-28 US US15/771,841 patent/US20180318165A1/en not_active Abandoned
- 2016-10-28 KR KR1020187013407A patent/KR102592358B1/en active IP Right Grant
- 2016-10-28 CA CA3003134A patent/CA3003134A1/en active Pending
- 2016-10-28 EP EP16860896.6A patent/EP3367987B1/en active Active
- 2016-10-28 CN CN201680075529.7A patent/CN108472157B/en active Active
- 2016-10-28 CN CN201680076316.6A patent/CN108472159B/en active Active
- 2016-10-28 CA CA3003018A patent/CA3003018A1/en active Pending
- 2016-10-28 RU RU2018119681A patent/RU2729930C2/en active
- 2016-10-28 DK DK16860896.6T patent/DK3367987T3/en active
- 2016-10-28 US US15/771,843 patent/US10449094B2/en active Active
- 2016-10-28 WO PCT/US2016/059291 patent/WO2017075331A1/en active Application Filing
- 2016-10-28 JP JP2018542985A patent/JP6703125B2/en active Active
-
2019
- 2019-09-05 US US16/561,121 patent/US11071652B2/en active Active
-
2020
- 2020-01-24 JP JP2020009747A patent/JP7280460B2/en active Active
-
2021
- 2021-01-14 AU AU2021200224A patent/AU2021200224A1/en not_active Abandoned
- 2021-06-18 US US17/351,749 patent/US11759368B2/en active Active
-
2023
- 2023-08-08 US US18/231,349 patent/US20230381027A1/en active Pending
Patent Citations (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2477403A (en) * | 1944-11-24 | 1949-07-26 | Owens Corning Fiberglass Corp | Surgical bandage |
US4667665A (en) * | 1984-08-16 | 1987-05-26 | Colin O'D. Offenhartz | Non-occlusive burn and trauma dressing |
US5409472A (en) * | 1989-08-03 | 1995-04-25 | Smith & Nephew Plc | Adhesive polymeric foam dressings |
US5052381A (en) * | 1990-03-19 | 1991-10-01 | The B. F. Goodrich Company | Adhesive wound dressing and perforated shield |
US5910125A (en) * | 1991-10-23 | 1999-06-08 | Cummings; Gary Wayne | Composite wound dressing with separable components |
US5607388A (en) * | 1994-06-16 | 1997-03-04 | Hercules Incorporated | Multi-purpose wound dressing |
US5578022A (en) * | 1995-04-12 | 1996-11-26 | Scherson; Daniel A. | Oxygen producing bandage and method |
US6756053B2 (en) * | 1995-07-28 | 2004-06-29 | Zars, Inc. | Controlled heat induced rapid delivery of pharmaceuticals from skin depot |
US5639568A (en) * | 1995-10-16 | 1997-06-17 | Aer Energy Resources, Inc. | Split anode for a dual air electrode cell |
US6171368B1 (en) * | 1998-11-06 | 2001-01-09 | Med-E-Cell | Gas extraction from closed containers |
US7238849B2 (en) * | 1999-03-17 | 2007-07-03 | Barbara Sheila Goldberg | Adhesive dispensing arrangement |
US6465709B1 (en) * | 1999-07-08 | 2002-10-15 | Johnson & Johnson Consumer Companies, Inc. | Exothermic bandage |
US6890553B1 (en) * | 1999-07-08 | 2005-05-10 | Johnson & Johnson Consumer Companies, Inc. | Exothermic topical delivery device |
US6336935B1 (en) * | 1999-09-15 | 2002-01-08 | The Procter & Gamble Company | Disposable thermal body wrap |
US7108440B1 (en) * | 1999-10-08 | 2006-09-19 | The Procter & Gamble Company | Applicator for distributing a substance onto a target surface |
US20030162095A1 (en) * | 2002-02-22 | 2003-08-28 | John Huang | Battery with a controlled release anode |
US6893453B2 (en) * | 2002-12-17 | 2005-05-17 | Kimberly-Clark Worldwide, Inc. | Thermal therapy pad with variable heat control |
US8012169B2 (en) * | 2003-09-08 | 2011-09-06 | Microlin, Llc | Electrochemical wound therapy device |
US7457667B2 (en) * | 2004-02-19 | 2008-11-25 | Silverleaf Medical Products, Inc. | Current producing surface for a wound dressing |
US20070055209A1 (en) * | 2005-09-07 | 2007-03-08 | Patel Harish A | Self contained wound dressing apparatus |
WO2007070151A1 (en) * | 2005-12-15 | 2007-06-21 | Kimberly-Clark Worldwide, Inc. | Therapeutic kit employing a thermal insert |
US20110045222A1 (en) * | 2009-08-19 | 2011-02-24 | Eastman Chemical Company | Oxygen-scavenging polymer blends suitable for use in packaging |
US8439894B1 (en) * | 2011-03-07 | 2013-05-14 | Larry W. Miller | Negative pressure bandage with internal storage chamber |
US20150159066A1 (en) * | 2011-11-25 | 2015-06-11 | Smith & Nephew Plc | Composition, apparatus, kit and method and uses thereof |
US20140109890A1 (en) * | 2012-10-19 | 2014-04-24 | Rechargeable Battery Corporation | Electrolyte Formulations For Oxygen Activated Portable Heater |
US9882196B2 (en) * | 2014-07-02 | 2018-01-30 | Pellion Technologies, Inc. | Multi-electrode electrochemical cell and method of making the same |
Cited By (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10898388B2 (en) | 2015-04-27 | 2021-01-26 | Smith & Nephew Plc | Reduced pressure apparatuses and methods |
US12059325B2 (en) | 2015-04-27 | 2024-08-13 | Smith & Nephew Plc | Reduced pressure apparatuses and methods |
US11759368B2 (en) | 2015-10-30 | 2023-09-19 | Aatru Medical, LLC | Wound therapy device and method |
US10449094B2 (en) * | 2015-10-30 | 2019-10-22 | Lorain County Community College Innovation Foundation | Wound therapy device and method |
US11071652B2 (en) | 2015-10-30 | 2021-07-27 | Lorain County Community College Innovation Foundation | Wound therapy device and method |
US11723809B2 (en) | 2016-03-07 | 2023-08-15 | Smith & Nephew Plc | Wound treatment apparatuses and methods with negative pressure source integrated into wound dressing |
US11285047B2 (en) | 2016-04-26 | 2022-03-29 | Smith & Nephew Plc | Wound dressings and methods of use with integrated negative pressure source having a fluid ingress inhibition component |
US11173240B2 (en) | 2016-05-03 | 2021-11-16 | Smith & Nephew Plc | Optimizing power transfer to negative pressure sources in negative pressure therapy systems |
US11096831B2 (en) | 2016-05-03 | 2021-08-24 | Smith & Nephew Plc | Negative pressure wound therapy device activation and control |
US11896465B2 (en) | 2016-05-03 | 2024-02-13 | Smith & Nephew Plc | Negative pressure wound therapy device activation and control |
US11305047B2 (en) | 2016-05-03 | 2022-04-19 | Smith & Nephew Plc | Systems and methods for driving negative pressure sources in negative pressure therapy systems |
US11648152B2 (en) | 2016-08-25 | 2023-05-16 | Smith & Nephew Plc | Absorbent negative pressure wound therapy dressing |
US11116669B2 (en) | 2016-08-25 | 2021-09-14 | Smith & Nephew Plc | Absorbent negative pressure wound therapy dressing |
US11564847B2 (en) | 2016-09-30 | 2023-01-31 | Smith & Nephew Plc | Negative pressure wound treatment apparatuses and methods with integrated electronics |
US11083683B2 (en) * | 2016-10-28 | 2021-08-10 | Coty Inc. | Topical composition |
US20190231670A1 (en) * | 2016-10-28 | 2019-08-01 | Coty Inc. | Topical composition |
US12005181B2 (en) | 2016-12-12 | 2024-06-11 | Smith & Nephew Plc | Pressure wound therapy status indication via external device |
US11123471B2 (en) | 2017-03-08 | 2021-09-21 | Smith & Nephew Plc | Negative pressure wound therapy device control in presence of fault condition |
US11160915B2 (en) | 2017-05-09 | 2021-11-02 | Smith & Nephew Plc | Redundant controls for negative pressure wound therapy systems |
US20190029917A1 (en) * | 2017-07-28 | 2019-01-31 | L'oreal | Multi-action lip-enhancement device |
US10905623B2 (en) * | 2017-07-28 | 2021-02-02 | L'oreal | Multi-action lip-enhancement device |
US11564845B2 (en) | 2017-09-13 | 2023-01-31 | Smith & Nephew Plc | Negative pressure wound treatment apparatuses and methods with integrated electronics |
US11701265B2 (en) | 2017-09-13 | 2023-07-18 | Smith & Nephew Plc | Negative pressure wound treatment apparatuses and methods with integrated electronics |
US11707564B2 (en) | 2017-11-01 | 2023-07-25 | Smith & Nephew Plc | Safe operation of integrated negative pressure wound treatment apparatuses |
US11497653B2 (en) | 2017-11-01 | 2022-11-15 | Smith & Nephew Plc | Negative pressure wound treatment apparatuses and methods with integrated electronics |
US11554203B2 (en) | 2017-11-01 | 2023-01-17 | Smith & Nephew Plc | Negative pressure wound treatment apparatuses and methods with integrated electronics |
US11992392B2 (en) * | 2017-11-01 | 2024-05-28 | Smith & Nephew Plc | Negative pressure wound treatment apparatuses and methods with integrated electronics |
US20210267638A1 (en) * | 2018-07-05 | 2021-09-02 | W.O.M. World Of Medicine Gmbh | Insufflation device with intelligent control of smoke evacuation |
USD999914S1 (en) | 2018-09-13 | 2023-09-26 | Smith & Nephew Plc | Medical dressing |
USD898925S1 (en) | 2018-09-13 | 2020-10-13 | Smith & Nephew Plc | Medical dressing |
US11819602B2 (en) | 2019-02-28 | 2023-11-21 | Aatru Medical, LLC | Chemical pump housing for negative pressure system |
US11083833B1 (en) | 2019-02-28 | 2021-08-10 | Aatru Medical, LLC | Chemical pump housing for negative pressure system |
WO2020176373A1 (en) * | 2019-02-28 | 2020-09-03 | Aatru Medical, LLC | Chemical pump housing for negative pressure system |
US12083263B2 (en) | 2019-03-20 | 2024-09-10 | Smith & Nephew Plc | Negative pressure wound treatment apparatuses and methods with integrated electronics |
US12005182B2 (en) | 2019-05-31 | 2024-06-11 | T.J.Smith And Nephew, Limited | Systems and methods for extending operational time of negative pressure wound treatment apparatuses |
WO2021021851A1 (en) * | 2019-07-30 | 2021-02-04 | Advanced Dressing, LLC | Dressing for providing low oxygen environment |
US20220257422A1 (en) * | 2019-07-30 | 2022-08-18 | Advanced Dressing, LLC | Dressing for providing low oxygen environment |
WO2021067340A1 (en) | 2019-10-03 | 2021-04-08 | Aatru Medical, LLC | Reduced pressure device having selectively deliverable electrolyte |
US10881553B1 (en) * | 2019-10-03 | 2021-01-05 | Advanced Dressing, LLC | Reduced pressure device having selectively deliverable electrolyte |
EP4037723A4 (en) * | 2019-10-03 | 2023-10-25 | Aatru Medical, LLC | Reduced pressure device having selectively deliverable electrolyte |
EP4041165A4 (en) * | 2019-10-03 | 2023-10-25 | Aatru Medical, LLC | Negative pressure treatment including mechanical and chemical pump |
US12097097B2 (en) | 2023-05-26 | 2024-09-24 | Smith & Nephew Plc | Negative pressure wound treatment apparatuses and methods with integrated electronics |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016344202B2 (en) | Tissue treatment device and method | |
US8439860B2 (en) | Oxygen-producing bandage with releasable oxygen source | |
CN1217641A (en) | Oxygen producing bandage | |
BR122019022437B1 (en) | WOUND THERAPY DEVICE | |
BR112018008402B1 (en) | WOUND THERAPY DEVICE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: LORAIN COUNTY COMMUNITY COLLEGE INNOVATION FOUNDAT Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DONDA, RUSSELL S.;MANICKAM, SUNDAR;MIDDAUGH, RICHARD L.;AND OTHERS;SIGNING DATES FROM 20180419 TO 20180428;REEL/FRAME:045796/0371 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCV | Information on status: appeal procedure |
Free format text: NOTICE OF APPEAL FILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCV | Information on status: appeal procedure |
Free format text: NOTICE OF APPEAL FILED |
|
STCV | Information on status: appeal procedure |
Free format text: APPEAL BRIEF (OR SUPPLEMENTAL BRIEF) ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCV | Information on status: appeal procedure |
Free format text: APPEAL BRIEF (OR SUPPLEMENTAL BRIEF) ENTERED AND FORWARDED TO EXAMINER |
|
STCV | Information on status: appeal procedure |
Free format text: EXAMINER'S ANSWER TO APPEAL BRIEF MAILED |
|
STCV | Information on status: appeal procedure |
Free format text: ON APPEAL -- AWAITING DECISION BY THE BOARD OF APPEALS |
|
AS | Assignment |
Owner name: ADVANCED DRESSINGS, LLC, OHIO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LORAIN COUNTY COMMUNITY COLLEGE INNOVATION FOUNDATION;REEL/FRAME:061238/0675 Effective date: 20220922 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION |